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ABSTRACT 
 
Dinsmore, Lauren E.  Physiologic, Psychologic, and Oxidative Stress Responses to  
Multimodal Exercise in an Endometrial Cancer Survivor Receiving High-Dose 
Chemotherapy: A Case Study Unpublished Master of Science, University of 
Northern Colorado, 2010. 
 
 
Exercise training, as a rehabilitative strategy, may be a vital factor in combatting 
the noxious toxicities related to cancer treatment. Research employing mixed modality 
exercise consistently demonstrates health benefits ranging from enhanced aerobic 
capacity and muscular strength to attenuated psychological distress. The primary aim of 
this case study was to examine the effects of exercise training on physiological and 
psychological parameters in an endometrial cancer survivor undergoing high-dose 
chemotherapy. Secondly, believed to play a role in toxicity development and progression, 
oxidative stress has yet to be studied in cancer survivors.  The second aim of this case 
study was to determine the effects of exercise on a selection of blood parameters 
including reactive carbonyl derivatives, a marker of protein degradation. The case study 
subject was a 60-yr-old female, diagnosed with stage IIIC1 endometrial cancer, 
undergoing chemotherapy (paclitaxel and carboplatin, [PC]). Assessments (e.g., body 
composition, VO2peak, 1-RM, pulmonary spirometry, fatigue and quality of life [QoL] 
indexes) were performed 1 day prior to the first PC cycle and again at 3- and 6-months. 
Exercise was performed 3 days/week (Tues, Thurs, and Sat) of each week for 21 weeks. 
Each 1 hour session consisted of treadmill walking and total body strength exercises. 
Blood pressure (BP), heart rate (HR), and ratings of perceived exertion (RPE) were
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recorded during training sessions. Over 141 calendar days, the case study completed 63 
exercise sessions (~45%). Physical characteristics remained relatively stable. VO2peak 
improved approx. 16% over the 6-month period (23.0 to 27.3 mL∙kg-1∙min-1). Decrements 
in lung function were evidenced by spirometry parameters, FVC (-10%) and FEV1 (-9%). 
Changes in global fatigue were not significant (p=.17) but affective and sensory subscales 
increased significantly between baseline and 3-months (p=.05). Subject-reported RPE 
scores during Phase I Nadir training were significantly lower than the prescribed range 
(p=.008). Also, Phase II Nadir scores were significantly lower than those reported in 
phase I (p=.003), suggesting the capacity to maintain exercise participation. Comparison 
of mean arterial pressure (MAP) between Phases I and II were not significantly different 
for Nadir (p=.74) or standard (p=.12) training. MAP was significantly reduced for Nadir 
compared to standard training (p=.005). ELISA results of oxidative stress markers 
illustrated a significant reduction of protein carbonyl concentration with programmed 
exercise (p=.03). Reduced protein oxidation may explicate the observed gains in 
muscular strength. Furthermore, results of complete hematology panels (e.g., WBC, 
RBC, HGB, and PLT) depicted a collective attenuation of treatment-related damage as 
per the recurring escalation toward initial (e.g., baseline) cellular concentrations. 
Multimodal exercise, as a remedial approach, appears to be well tolerated and appropriate 
for the preservation of physical and psychological capacities in an endometrial cancer 
survivor undergoing treatment. 
 v 
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CHAPTER I 
INTRODUCTION 
 Owing to strides in disease management and early detection, the concept of 
cancer survivorship is no longer a fruitless endeavor but more often the anticipated 
outcome of clinician and patient alike. Alas, accompanying improved survivorship are 
the persistent toxicities related to treatment. Historically, patients receiving anticancer 
treatment have been advised to reduce physical activity and seek rest. Yet, there is 
growing evidence contesting obsolete rehabilitative strategies in order to avoid self-
perpetuated conditions (e.g., fatigue). With attention directed at tackling corrosive 
toxicities, the pursuit for new remedial strategies is a welcomed challenge to prolong 
survival. Therapeutic aims focus on improving the quality and quantity of life after 
cancer diagnosis.  
Cancer remains the second leading cause of death in the United States, as 
indicated by the National Cancer Institute (NCI, 2010a). Despite the high mortality rates 
associated with certain cancers, prospects for survival continue to improve. According to 
the American Cancer Society (ACS), the survivor population in the United States 
comprises approximately 12 million individuals. Globally, this number climbs to nearly 
20 million, with about 285,000 people being added on an annual basis (ACS, 2009a). 
While tumor biology has long been central to oncology research, patients‟ 
expectations for a better quality of life (QoL) drives research efforts to focus on enhanced 
survivorship care. By cancer site, there is a disproportion of available research.
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Disparities are justified by a survivor population comprised of 50% breast and prostate 
diagnoses with colon, hematological, and endometrial malignancies each accounting for 
only about 10% (Hewitt, Greenfield & Stovall, 2005). Needless to say, the safe and 
efficacious management of cancer-related toxicities requires analysis and validation 
across cancer sites (Visovsky & Dvorak, 2005). 
Outlined by Courneya and Friedenreich (2007), the Cancer Control Framework 
suggests specific disease-related stages exist along a “logical continuum” and illustrate 
the transition from prescreening to active treatment and survivorship care. Implications 
associated with a particular stage may be involved with and/or advance psychological and 
physiological impairment. Specifically, medical interventions that improve the outlook of 
surviving cancer are undertaken at the expense of treatment-induced toxicities. The most 
common treatment modalities (e.g., surgery, radiotherapy, and chemotherapy) elicit a 
wide range of well-documented toxicities that can generate persistent damage long after 
treatment is complete.  
Systemic therapy (e.g., chemotherapy drugs) is associated with a range of chronic 
debilitations (Schneider, Dennehy & Carter, 2003). The cumulative nature of 
chemotherapeutic agents augments the severity and extent of toxicities. Irradiation 
therapy elicits significant damage similar to chemotherapy, especially amplified in 
targeted tissue. This development of toxicities following treatment is presumed to be 
induced by a state of amplified oxidative stress (Chen, Jungsuwadee, Vore, Butterfield & 
St Clair, 2007).  
Prolonged, intensive treatments elicit whole-body toxicities and compromise the 
integrity of healthy tissue through the generation of free radicals (Lucia, Earnest & Pérez, 
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2003; Loft & Poulsen, 1996). Collective toxicities foster a degradation of physical and 
emotional functioning (Beesley, Eakin, Janda & Battistutta, 2008). With the deterioration 
of patients‟ psychologic well-being, cancer-related fatigue and waning QoL are 
amplified. As fatigue is activity-limiting by nature, somatic perceptions can remain for 
years. 
According to Smets, Garssen, Schuster-Uitterhoeve and Haes (1993), the 
prevalence of fatigue, irrespective of disease site or stage, is approximately 70%, making 
to the most frequently reported symptom in cancer patients (Visovsky & Dvorak, 2005; 
Dimeo, 2001). A complex etiology complicates alleviation (Smets et al., 1993). The well-
meaning advice to combat fatigue paradoxically compounds symptoms. As patients take 
on sedentary habits, fatigue is self-perpetuated through catabolic pathways and detraining 
(Courneya, 2003).  
By contrast, participation in physical activity is gaining credibility as a restorative 
approach, boasting an antidote for a range of toxicities to enhance QoL and reduce 
fatigue (Schneider, Hsieh, Sprod, Carter & Hayward, 2007; Speck, Courneya, Mâsse, 
Duval & Schmitz, 2009). The explosion of novel research that has surfaced will 
ultimately affect medical practice to revolutionize techniques employed to prevent, 
attenuate, and restore treatment-induced tribulations.  
Due to high diagnosis rates, the majority of research has investigated the effects 
of exercise in breast and prostate patients (Courneya, Friedenreich, Arthur & Bobick, 
1999). In this population, exercise programming has led to conclusive improvements in 
psychologic status, subjective fatigue, and cardiorespiratory fitness level (Burnham & 
Wilcox, 2002; van Weert, Hoekstra-Weebers & Grol, 2005). It is not sensible to 
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extrapolate findings to all cancer sites and stages; however, the body of evidence 
continues to grow in support of exercise as a collective rehabilitative approach for cancer 
survivors (Dimeo, 2001; Schneider et al., 2003). 
A review by Schmitz et al. (2010) examined available literature in support of both 
the efficacy and safety of exercise training in cancer survivors. Evidence was gathered 
from completed randomized controlled trials (RCT) and assessed for each cancer site. 
Cancers of the prostate and colon have been evaluated in 12 and 4 studies, respectively. 
The outcomes of exercise programming for survivors of hematologic malignancies either 
treated with hematopoietic stem cell transplantation (HSCT) or in the absence of HSCT, 
have been evaluated in 11 and 4 studies, respectively.  
A severe deficit of exercise research in gynecological cancers is evidenced by a 
single completed RCT at the current time. While 5 studies have used mixed samples, 
incorporating a small number of gynecologic patients (n=5-15), only one intervention has 
exclusively assessed this specific population.  
Considered a weight loss intervention, this gynecological RCT by von Gruenigen 
et al. (2008) was conducted in a sample of endometrial cancer survivors. Specified 
inclusion criteria required that subjects be of post-treatment status and overweight/obese 
classification. With the primary focus of this 6-month intervention on weight change, 
physical activity served as a secondary health outcome. Allocated pedometers, used in 
place of a structured exercise program, made conclusions in regard to the effects of 
physical activity seedy and unreliable.  
Research has yet to evaluate the effects of a structured exercise program in 
endometrial cancer survivors. Moreover, most exercise studies conducted in oncology 
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research implement interventions after the completion of treatment. Along with the lack 
of research focused on exercise during treatment, even rarer is it to find a study that has 
collected baseline measures prior to antineoplastic treatment. Gathering baseline values 
for parameters of interest can only expand the understanding of toxicity development and 
the benefits of exercise. 
Therefore, the purpose of this case study was to investigate the effects of exercise 
training on physical capacity and psychological functioning in an endometrial cancer 
survivor undergoing high-dose chemotherapy. Also, knowing that exercise regulates the 
generation of reactive oxygen species (ROS) in a range of chronic diseases, the second 
aim of this study was to determine the effects of exercise on reactive carbonyl 
derivatives, a marker or protein oxidative stress. 
Statement of Purpose 
 To examine the effects of a 6-month multimodal exercise intervention on 
physiologic and psychologic functioning and a selection of blood markers in an 
endometrial cancer survivor receiving high-dose chemotherapy. 
Research Hypotheses 
H1 Multimodal exercise will ameliorate cancer-related fatigue and 
preserve QoL over the course of high-dose chemotherapy cycles. 
 
H2 Aerobic capacity and muscular strength, as per VO2peak and 1-RM, 
respectively, will be sustained through an individualized exercise plan. 
 
H3 The training intervention will attenuate oxidative stress damage, 
as evidenced by a reduced protein carbonyl concentration. 
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CHAPTER II 
REVIEW OF LITERATURE 
Cancer Overview: Principles & Pathology  
According to the National Coalition on Cancer Survivorship, a cancer survivor 
constitutes any person diagnosed with cancer, from the time of discovery and for the 
entirety of his or here life thereafter (Speck et al., 2009). Presently, this clinical 
population is comprised of 12 million individuals and continues to expand (Schmitz et 
al., 2010).  
The growth is attributable to enhanced diagnostic tools and more effective 
antineoplastics. Moreover, as noted by the National Cancer Institute‟s 2009-2010 Cancer 
Trend Progress Report, a reduction in disease incidence and death rate across all cancers 
has been reported since the turn of the twenty-first century (NCI, 2010a). In spite of 
continued progress, cancer will claim approximately 562,000 lives this year, making it 
the second most common cause of death in the United States (Mariotto et al., 2008). Of 
the 1.5 million diagnoses, leading tumor sites in men and women are prostate and breast, 
respectively (ACS, 2009a).  
In recent decades, research contributions have enhanced the understanding of 
cancer to a new, unprecedented level. The primary focus of research has long been tumor 
biology and the associated intricacies, with less attention devoted to host biology and 
patient care. The evolving avenue of translational research relates molecular biology to 
7 
 
 
 
patient therapeutic and diagnostic care, uniting the human and animal research models 
(Song, Samulski & Van Dyke, 2008). Once diametrically separated, biological 
mechanisms can now be used by the clinician to improve disease evaluation and remedial 
management. Theories of cell cycle kinetics provide insight into disease origin and 
progression. The cell cycle is comprised of a series of precisely programmed events 
which regulate proliferation. When the distinct cycle phases, G0, G1, S, G2, and M, occur 
in the anticipated procession, division occurs under appropriate circumstances in a timely 
manner (Weinberg, 2007). Because proteins act as modulators in growth and apoptotic 
pathways, disturbance of protein regulation can propagate deviant growth patterns and 
advance tumorigenesis (Macheda, Rogers & Best, 2005). 
Errors in intrinsically normal molecular pathways remain central to cancer 
genesis. Signaling pathways involved in homeostasis, cellular proliferation and 
differentiation, and apoptosis demonstrate interconnectivity; aberrations in pathways 
concerned with basic and essential processes can promote disease phenotype (Weinberg, 
2007). Under normal circumstances, abnormal or superfluous cells are managed through 
apoptotic pathways. Yet, deviations can instigate hyperproliferation (Schneider et al., 
2003). The volume of mechanism-specific cell types augments the scope of obstacles 
posed by cancer.  Often, the same mechanism responsible for cellular diversity dictates 
disease progression (Song et al., 2008).  
In cancer cells, feedback mechanisms responsible for cellular turnover are 
disconcerted leading to the formation of irregular, undifferentiated masses of cells, or 
tumors. If not removed or destroyed, tumors have the potential for direct penetration of 
contiguous tissue. A metastatic disease has penetrated the lymphatic and blood vessels, 
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utilizing the bloodstream to colonize throughout the body. Invasion and metastasis allow 
cancer cells to leave the primary tumor site, inhabit distant tissues and spread throughout 
the body (Minn & Massaqué, 2008).Tumor development relies on a constant supply of 
fuel in order to maintain cellular processes. Like normal cells, malignant cells employ 
shared metabolic pathways to sustain energy production.   
A Duke University study by Sonveaux et al. (2008) elucidated upon the 
bioenergetic pathways exploited by cancerous tumors. Tumors, considered heterogeneous 
tissue, are comprised of oxygenated and hypoxic cellular regions. Both the oxygenated 
and hypoxic cells utilize glucose as the primary energy metabolite (Sonveaux et al., 
2008). Glucose is reduced in a cascade of chemical reactions which constitutes glycolysis 
(Powers & Howley, 2007). Hypoxic and aerobic cells yield distinct glycolytic end-
products, lactate and pyruvate, respectively. This favorable characteristic ensures energy 
substrates for the metabolically-discrete cells (Sonveaux et al., 2008). Researchers refer 
to this metabolic partnership as an “intratumoral metabolic symbiosis” (Semenza, 2008). 
This cyclic production-utilization drives tumorogenesis and progression. 
The lactate produced in hypoxic cellular regions is taken up by aerobic cells and 
serves as a primary substrate for oxidative cancer cells. Hypoxic tumor cell activity is 
anaerobic due to limited oxygen availability and as a result, less energy is produced 
(Powers & Howley, 2007). To counteract the reduced rate of energy production, hypoxic 
cells augment glucose uptake to remain homeostatic (Macheda et al., 2005). 
Consequentially, healthy cells are starved of nutrients and will quickly become necrotic, 
allowing disease invasion and metastasis (Heiden, 2010). 
9 
 
 
 
The structure and activity of a cancer cell is highly unorganized in contrast to 
healthy cells (Schneider et al., 2003).  A loss of cellular differentiation and atypical 
mitotic processes instigate failure of host tissue. The origins of malignancy are 
widespread. Etiological factors can range from exposure to chemical toxins to heritable 
traits and nutrition status. Carcinogenesis, or the process by which healthy cells become 
cancerous, is attributed to an array of established risk factors. Atypical cellular processes 
are instigated by carcinogen assault (Ehrman, Gordon, Visich & Keteyian, 2003). Since 
1971, the International Agency for Research on Cancer (IARC) has evaluated 900 
environmental factors to determine the carcinogenic potential of each. Approximately 
400 agents have been deemed either carcinogenic, probably carcinogenic, or possibly 
carcinogenic (IACR, 2008).  
There is evidence to support that most cancers have a strong environmental 
etiology. Doll and Peto (1981) evaluated a selection of lifestyle factors to determine the 
extent modification played in attenuating cancer incidence. Researchers speculated that 
35% of cancer mortality in the United States could be prevented by alterations in diet, 
indicating that a considerable proportion of diagnoses could be avoided (Doll & Peto, 
1981). 
 Nutritional status, physical activity, and body size all interact to regulate energy 
balance. There is substantial epidemiological evidence to support that excess weight and 
obesity (BMI >25) contributes to various endocrine and metabolic perturbations, which 
can trigger carcinogenesis (Fair & Montgomery, 2009). Specifically, adiposity, resulting 
from surfeit caloric intake relative to energy expenditure, produces a positive energy 
balance (PEB). It is posited that a PEB has potential to disrupt growth factors, 
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inflammatory markers, and hormones. It has been suggested that inflammatory signaling 
has etiological potential (Henderson & Bernstein, 2008). Energy imbalances can be 
piloted by a lack of participation in physical activity, as well. In fact, an inverse 
relationship has been postulated between physical activity and cancer 
incidence/mortality, supporting regular exercise as a means of reducing cancer risk 
(Michels & Willett, 2008).  
It has been postulated that oxidative stress is implicated with cancer etiology (Loft 
& Poulsen, 1996). Oxidative stress reflects a state in which the generation of reactive 
oxygen species (ROS) exceeds adaptive capacities of the antioxidant defense system 
(Oberley, 2001). Produced as the byproduct of respiration and other biochemical 
reactions in which oxygen is involved, ROS fall under the intricate regulation of the 
antioxidant defense system. When properly managed, ROS maintain a breadth of 
physiological processes, including signal transduction and regulation of mitochondrial 
enzyme activity. With a reduction of antioxidant enzymes as per aging, Diabetes, 
ischemia/reperfusion injury, cancer, etc., the concentration of ROS can quickly climb to 
toxic levels (Valko et al., 2006). 
Just as carcinogens can act upon any somatic cell, the risk of cancer threatens all 
individuals. Cancer risk can be evaluated as the probability of cancer development over 
the course of the entire lifetime (lifetime risk); men and women in the United States have 
a lifetime cancer risk of slightly less than 1 in 2 and a little more than 1 in 3, respectively 
(ACS, 2009a). Lifetime risk does not assess the risk of developing specific cancers. More 
often, risk is assessed based on the relationship strength between particular risk factors 
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and certain cancers (relative risk). Relative risk provides useful insight for the individual 
and is more appropriate for assessing the threat posed by a particular cancer. 
Genetic mutations, capable of eliciting tumorogenesis, demand appropriate 
disease classification for accurate diagnosis and therapy prescription. Based on the 
location and tissue type affected, tumors are broadly categorized. Cancers arises in the 
form of solid tumors or serous and hematological malignancies. 
Cancers involving solid tumor formation include carcinomas and sarcomas. 
Carcinomas, originating in the epithelial lining of various tissues, are extremely common 
and account for nearly 90% of all diagnoses. Only about 2% of cancers develop as 
sarcomas, or invasive tumors of the connective tissue, bone, muscle, cartilage, and fat 
(Schneider et al., 2003).  
Serous cancers include leukemia, melanoma and lymphoma. Leukemia involves 
the abnormal production of white blood cells. Responsible for defense against pathogenic 
invasion, leukemia can leave the immune system compromised. Melanomas and 
lymphomas affect somatic melanocytes and lymphocytes, respectively (Schneider et al., 
2003).  Extensive histological evaluation of the tumor is obligatory in order to ascertain 
disease trajectory and accurately stage the disease. 
In an effort to ease ambiguity in clinical staging and diagnosis, The American 
Joint Committee on Cancer (AJCC) manages revisions made to The AJCC Cancer 
Staging Handbook, which evaluates specific anatomic criteria to facilitate cancer stage 
identification. Considered by many to be the gold standard in oncology classification, the 
AJCC tumor node metastasis (TNM) system is used by physicians and health care 
professionals in order to construct universal descriptions of neoplastic diseases. A 
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standard classification system is essential to assigning treatment plans and the assessment 
of outcomes following disease management (Edge et al., 2010).  
The anatomic criteria evaluated by the TNM system includes: primary tumor size 
and contiguous extension (T), presence/absence and extent of lymph node involvement 
(N), and presence/absence of distant metastasis (M). From a clinical evaluation of the 
TNM components, disease progression is assessed and an appropriate cancer stage 
determined (Schneider et al., 2003). AJCC and its collaborative organizations require 
sufficient time to evaluate newly acquired clinical data and judge potential benefits for 
improved prognosis (Edge et al., 2010). Even with periodic amendment to the staging 
system every 6-8 years, diagnoses based on thorough clinical assessment are not 
infallible.  
The expanding population of cancer survivors poses the well-received challenge 
of addressing the individual needs of long-term survivors (Aziz & Rowland, 2003). The 
aim of continued care is based on patients‟ traits (e.g., age, gender, race), cancer type, 
existence of comorbidities, etc. Attention is now focused on strategies to transition the 
cancer survivor back into a disease-free life and the potential adjuvant strategies to foster 
this shift.  
Endometrial Cancer 
Cancers of the corpus uteri (body of the uterus) involve carcinomas and sarcomas 
of the endometrial epithelial lining. Sarcomas of the uterine stroma and muscle cells are 
less common and associated with poorer outlooks (ACS, 2009b).  Endometrial cancer is 
the most prevalent female gynecological malignancy, accounting for 6% of all female 
cancers. Close behind cancers of the breast, lung, and colon, endometrial carcinoma is the 
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fourth most frequent killer of women in the United States (Rodriguez, 2001a; NCI, 2009; 
Dizon, 2010). The well-established warning sign associated with endometrial cancer, 
postmenopausal or abnormal bleeding, affords a high incidence of stage I diagnoses and 
frequent curable prognoses. The incidence of endometrial cancer has declined by 
approximately 0.5% each year since 1997 and the improvements in 5-year survival rates 
for local, regional, and distant cancers, 96%, 68%, and 24%, respectively, attest clinical 
strides (NCI, 2010a). 
Adenocarcinoma, the most common form of endometrial carcinoma, affects the 
gland-forming cells of the endometrium. Adenocarcinoma subtypes are recognized via 
distinct pathological features. „Typical‟ adenocarcinomas, known as endometrioid 
adenocarcinoma, account for 90% of endometrial cancers (Chu, Lin, & Rubin, 2008). 
More rare, „high risk‟ adenocarcinomas include clear-cell adenocarcinoma and papillary 
serous adenocarcinoma which develop in 5% and 6% of all cases, respectively. These 
subtypes are poorly differentiated, highly aggressive, and metastasize rapidly. Five-year 
survival outlooks are very poor for high-risk carcinomas (Rodriguez, 2001b; ACS, 
2009b).  
 Disease stage is highly predictive of survival. Accordingly, the staging prognostic 
criteria should be capable of scrutinizing between minute histological and pathological 
differences. Diagnostic tests, such as the uterine biopsy and endocervical dilatation and 
curettage (D&C), are performed to evaluate uterine pathology. D&C, considered the gold 
standard of diagnostic tools, can decipher glandular abnormalities in epithelium of a 
thickness <5mm (ACS, 2009b). The criterion, serum CA-125, is not readily assessed 
across all cancer diagnoses, but plays a crucial role in endometrial cancer. CA-125 levels 
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>20 U/ml are indicative of deep myometrial invasion and metastatic assault. The criteria 
of histologic subtype, grade of differentiation, and stage at presentation are the most 
influential for prognosis.  
 Whether a carcinoma is classified as having „high-risk‟ or „typical‟ histology is 
dependent on the degree of differentiation of gland-forming cells. Cancer grade is an 
evaluation of endometrial architectural and appearance of glands formed by malignant 
cells in relation to those formed by healthy endometrium.  
“High grade” cancers are associated with a lack of cellular arrangement in which 
gland formation is not possible. Grade III cancers tend to be aggressive due to haphazard 
organization and rapid growth patterns. Typically, less than half of cancerous tissue is 
capable of forming glands leading to poor prognoses (NCI, 2009). Grades I and II show 
glandular growth patterns of >95% and 50-95%, respectively. Lower grades are typically 
associated with better outlooks and slower disease progression. Cancer grade is crucial in 
diagnostic staging, as it can be predictive of metastasis and nodal involvement 
(Rodriguez, 2001b; Chu et al., 2008).  
Recently, staging of corpus uteri malignancies has changed to a surgical system, 
relying less upon the previously employed clinical staging. Tissue removed during 
surgical assessment (i.e. uterine biopsy and/or curettage) allows for evaluation of local, 
regional, and metastatic development; tissue evaluation is used to assign the appropriate 
stage. Implemented by the International Federation of Gynecology and Obstetrics 
(FIGO), surgical staging better assesses lymph node involvement and extrauterine 
metastasis (Creasman, 2009). For gynecological cancers, FIGO staging is often used in 
place of the AJCC system due to specific evaluation of uterine histopathology and 
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cytology. Five-year survival rates for stage I and II carcinomas are 83% and 73%, 
respectively. High-risk carcinomas, III and IV, reveal 5-year survival rates of 52% and 
27%, respectively (Rodriguez, 2001b). 
Endometrial cancer has been associated with a selection of etiological factors. 
Chronic estrogen exposure is a well-recognized risk factor in disease development. 
Adenocarcinomas that develop due to estrogen stimulation are classified as Type I (Chu 
et al., 2008).  Pathologically discrete, type II cancer development is not attributable to 
prolonged hormone exposure, as indicated by rare serous carcinomas. Type II 
pathogenesis is not well characterized, suggesting an explanation for the associated poor 
survivorship (Rodriguez, 2001b).  
Many modifiable factors (e.g., nutrition, exercise, etc.) augment risk of 
adenocarcinoma development. High fat diets in Western cultures evidence climbing rates 
of obesity. A prominent risk factor, obesity increases endometrial cancer 
incidence/mortality rates. Moreover, obese women have elevated circulating estrogens 
due to adipocyte conversion of androstenedione to estrone (Chu et al., 2008). In contrast 
to her healthy counterparts, an obese woman with an excess weight of 30 lb or 50 lb 
increases her risk of endometrial cancer by 3x and 10x, respectively.  
Women who do not bear children during the lifespan (nulliparity) endure chronic, 
uninterrupted estrogen exposure, which can increase the risk of endometrial cancer 2- to 
5-fold (Rodriguez, 2001a). In contrast, pregnancy is considered a progestational state, 
which reduces endometrial cancer risk. Similar to the biological effects elicited during 
pregnancy, progestin regimens elicit parallel effects and reduce cancer risk. Certain 
clinical conditions, diabetes mellitus and hypertension, predispose an individual to 
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endometrial cancer, as result of elevated endogenous estrogen (ACS, 2009a). A history of 
pelvic irradiation along with various imaging techniques (i.e. x-rays, radioactive scans) 
elevates the risk of cancer, as well.  
The incidence of endometrial cancer increases linearly with age; unfortunately, 
advanced age is inversely related to 5-year survival rates. Endometrial cancer is most 
frequently diagnosed in Caucasians, attributable to exogenous estrogen therapy employed 
for menopausal syndrome. Estrogen exposure elicits hyper-proliferative activity in 
endometrial cells. Consequently, the likelihood of somatic mutations increases (Dizon, 
2010).  A woman ingesting standard doses of estrogen, without concurrent progestational 
agents, increases her risk of endometrial cancer 9.5x (Rodriguez, 2001a). Such etiological 
factors can ultimately influence the selection of appropriate treatment modalities. 
The course of treatment undertaken is closely related to the tumor histopathology, 
as it explicates upon disease trajectory and prognosis. In 95% of all endometrial cancer 
cases, removal of the uterus with bilateral fallopian tubes and ovaries (e.g., total 
abdominal hysterectomy with bilateral salpingo oopherectomy [TAH-BSO]) serves as the 
primary surgical procedure. Tissues removed during TAH-BSO undergo cytologic 
evaluation in order to stage the cancer. Due to the poor differentiation and myometrial 
invasion associated with grade III malignancies, pelvic and para-aortic node sampling is 
recommended to assess the extent of metastasis. Removal of lymph nodes 
(lymphadenectomy) for comprehensive analysis will not only reveal disease progression 
but can arrest further metastasis. In early-stage cancers, combined TAH-BSO and 
lymphadenectomy treatments may serve as an adequate course of therapy to combat 
cancer growth (Rodriguez, 2001b).   
17 
 
 
 
Advanced or recurrent cancers often necessitate adjuvant therapies such as 
chemotherapy or whole pelvic irradiation. Poor prognoses commonly associated with 
late-stage carcinomas accentuate the need for innovative treatment options. Showing 
promise in the late stages of clinical trials, epothilones represent a new class of 
chemotherapeutic microtubule-stabilizing drugs classified as cytotoxic metabolites. 
Epothilones may be successful in treating advanced adenocarcinoma resistant to standard 
taxane and/or anthracycline therapies (Lee et al., 2009).  
Endometrial cancer survivorship is highly related to staging at the time of disease 
presentation. Yet, while early-stage diagnoses lead to promising outlooks in about 75% of 
women, it is projected that cancer of the uterine corpus will claim approximately 7,800 
lives this year (ACS, 2009a). Though mortality rates have stabilized since the early 
nineties, this trend does not demonstrate strides in survivorship made in other areas of 
oncology. Current statistics beg for advancement of diagnostic tools and medical 
treatments. 
Principles of Chemotherapy & Radiation 
The primary objective of antineoplastic drugs is to prevent or delay rapid growth 
patterns of cancer cells. An inability to manage the spread of disease can result in the 
unrelenting necrosis of healthy tissue and, ultimately, the failure of organ systems leading 
to death. The appropriate course of action is based on a patient‟s cancer type and the 
metastatic trajectory. Additional factors that affect treatment selection include the 
existence of comorbidities at the time of diagnosis or prior exposure to antineoplastics in 
those individuals with recurrent cancer or second neoplasms (Kumar et al., 2009).  
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Recurrent cancers treated previously using chemotherapeutic agents may be 
resistant to second-line chemotherapy (Dizon, 2010). The development of 
chemoresistance is often related to the overexpression of specific molecular targets. Two 
commonly susceptible targets, the ATP-binding cassette (ABC) transporter proteins and 
the P-glycoproteins, elicit unregulated gene expression (Leslie, Deeley & Cole, 2005). 
Constitutive expression of certain proteins can disrupt transport and apoptotic pathways. 
Chemoresistance is associated with reduced chemotherapeutic agent found in tumor cells 
due to low activity of transport proteins (Fojo & Menefee, 2007). As a result, 
proliferation continues.  
The stage of cancer dictates the goal of treatment; common aims include curative 
intent, control, and palliation of the disease. Treatments with curative intent remove the 
tumor, anticipating that it will not return. While a curative outcome may be the objective, 
it is not a certainty (ACS, 2010). Early-stage cancers, without metastatic qualities, are 
more typically associated with curative intent therapies. Disease control often serves as a 
more practical aim. A disease-free life may not be feasible, yet the spread of cancer may 
be controlled and monitored (Lawrence, Ten Haken & Giaccia, 2008).  
Palliative therapies are most often employed in patients‟ characteristic of 
inoperable cancer, advanced stage disease, and contraindicative comorbidities. The 
premise behind palliation is to relieve symptoms brought on by the disease to improve the 
patient‟s QoL. Designing treatment plans with each patient in mind is critical to ensure 
that therapy is precise, effective, and as minimally harmful to healthy tissues as possible. 
Surgical removal of cancerous tissue serves as the most common primary 
treatment (Schneider et al., 2003). In an effort to reduce the size of the cancerous mass 
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prior to dissection, neoadjuvant treatments often precede surgery, with the intent of 
making subsequent treatments more effective. Following tumor excision, secondary 
treatments are commonly administered to destroy and residual malignant cells.  
Subsequent treatments are classified as adjuvant therapies (NCI, 2010c). While surgery is 
effective in removing the bulk of the cancer, adjuvant utilities are employed if threat of 
metastasis exists.  
Chemotherapy and radiotherapy are extensively employed as second-line 
treatment. More than 50% of cancer patients receive radiation during the course of his or 
her illness (Khan, 2003). Radiation energy is administered as either photons or particles. 
The interaction of radiation with biological material results in ionization. When ionizing 
radiation is absorbed by chromosomal DNA, cellular inactivation and death ultimately 
occur (Lawrence et al., 2008).  
Much like surgical oncology, radiotherapy is considered a local treatment. Cells 
in the irradiated target tissue lose the ability to divide due to breaks in double-stranded 
DNA, making growth and replication impossible (NCI, 2009). This inhibition of the cell-
cycle can lead to cellular apoptosis depending on the radiotherapy dosage.  
Radiation therapy is typically administered either as an external high-energy 
photon beam or internally-positioned radioactive source (ACS, 2010). The particular 
technique employed is based on cancer location and stage. Variability of patient 
responses to treatment necessitates adjustable dosage schedules relative to each patient. 
Internal radiation (brachytherapy) involves placing the radiation source inside the body. 
Radioactive sources can be placed within the tumor itself as interstitial brachytherapy or 
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within the surgical cavities near the tumor as intra-cavitary brachytherapy. The 
radioactive source takes on a solid form as seeds, pellets, or capsules (NCI, 2010b).  
Rapid, uncontrolled growth patterns make cancer cells extremely radiosensitive. 
This augmented sensitivity promotes susceptibility to genetic damage and apoptosis 
(ACS, 2010). Unfortunately, the effects of radiation are not limited to dividing cancer 
cells. Healthy cells undergoing mitosis in close proximity to target tissue can endure the 
therapy-induced damage (Lawrence et al., 2008). The side effects experienced amid 
radiation reflect healthy cell destruction. With each treatment, the body attempts to 
maintain energy balance between cancer cell destruction and the sparing of surrounding 
tissue.  
Radiation tolerance varies for tissues throughout the body. The amount of 
radiation a particular tissue absorbs refers to the radiation dosage (ACS, 2010). In order 
to maximize cancer cell destruction with minimal damage to healthy tissue, doctors 
divide the total dosage into multiple, smaller fractions. Typically, fractional doses are 
administered daily for a specified amount of time, allowing for recovery in nearby 
healthy tissue (Food and Drug Administration [FDA], 2009).   
Assessment of radiotherapy-induced damage between malignant and healthy cells 
is exemplary of the therapeutic ratio, which yields the risk: benefit profile (Bioce, 2009, 
March).The selected radiation dose should control tumor growth with negligible 
production of deleterious toxicities (Shafiq, Barton, Noble, Lemer & Donaldson, 2009). 
 Higher doses of radiotherapy are commonly administered to regions harboring 
the bulk of the tumor, while neighboring tissue, suspect of occult disease and nodal 
involvement, will receive abridged dosage to address the threat of metastasis. Curative 
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intent treatments often justify heightened dosage schedules encompassing enlarged 
anatomical areas. As a result extensive tissue is affected and organ preservation becomes 
a primary concern.  Though radiation frequently contributes to curative outcomes, it can 
also drive the development of second or recurrent neoplasms (FDA, 2009). 
In advanced, metastatic disease, chemotherapeutic agents are often used in lieu of 
or in combination with other treatment modalities. Regularly utilized to address the 
limited life expectancy associated with advanced cancer, chemotherapy refers to the 
systemic treatment of cancer; chemotherapeutic agents are most commonly administered 
via intravenous delivery (Schneider et al., 2003).  The efficacy of chemotherapy regimens 
demand a comprehension of the molecular pathways and mechanisms involved in both 
malignant and normal cells. The field of cancer genetics elucidates upon the drug kinetics 
and the disciplines of pharmacokinetics and pharmacodynamics. Cancer genetics can be 
used to construct strategies that reduce interpatient variability and augment consistency 
of therapeutic effects. The absorptive and metabolic actions associated with a particular 
agent shed light on the clinical effects (e.g., efficacy and toxicity) elicited within the body 
(Takimoto & Chee, 2008). 
Cytotoxic drugs are classified into broad groups on the basis of chemical 
properties and structure. Common drug classes include, but are not limited to, platinum-
based agents (e.g., Carboplatin) and antimicrotubule agents (e.g., Paxclitaxel). Cancer 
site and stage, previous chemotherapy exposure, and contraindicative health conditions 
dictate which drug class/analog will be the most therapeutic (ACS, 2010).  
Single-agent monotherapy has not historically revealed the efficacy of 
combination chemotherapy (DeVita & Chu, 2008). While each drug elicits a scope of 
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specific effects, the success of combinational therapy is attributable to interactions 
between antineoplastic agents. If considering combination chemotherapy, established 
optimal dosage schedules of each drug should be maintained (Weinberg, 2007). Because 
overlap of toxicity profiles has potential to induce lethal effects, all drug interactions and 
risks are evaluated. 
Genetic variability accounts for the vast array of patient reactions to antitumor 
therapies. Tailoring a treatment approach to each patient is the central theme to the “art of 
medicine”. Discrepancies of responses to chemotherapy regimens may require 
manipulation of the dose intensity, or the amount of drug per unit time (DeVita & Chu, 
2008). Dose intensity is established from the time allotted for administration. There is a 
well-established relationship between dose intensity and treatment outcome (Takimoto & 
Chee, 2008).  
Summation dose intensity is used to predict treatment outcomes in combination 
therapies. As the number of antitumor agents administered at full therapeutic dose 
increases, the cure rate linearly rises (Berglund, Bolund, Fornander, Rutqvist & Sjoden, 
1991). Coalescing mechanism-specific drugs often leads to augmented efficacy. 
Treatment outcomes are highly related to the patient‟s capacity to tolerate a multi-agent 
course of therapy. While effective dose intensities lead to tumor destruction and 
optimistic prognoses, augmented delivery can elicit deleterious toxicities. Postponement 
of successive drug cycles is related to poor outlooks (Edge et al., 2010). A topic of 
concern, research addresses the need for effective combinational therapies with minimal 
side effects. 
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A NCI clinical trial evaluated the efficacy and toxicity between two of the most 
popular combination therapies, carboplatin and paclitaxel (collectively referred to as PC) 
versus Doxorubicin (Dox), cisplatin and paclitaxel. Despite the fact that Dox serves as an 
effective antitumor agent, its high toxicity profile deters many clinicians. Researchers 
conclude that administration of carboplatin with concurrent paclitaxel was just as 
effective at killing tumor cells with less destructive toxicities (DiSaia, 2008). 
The efficacy of platinum-based Carboplatin is based on erroneous binding 
patterns of nucleic acid bases (Reed, 2008). Deterioration of the double stranded helix 
structure induces genetic damage to inhibit cellular reproduction (Ross, 1972).  The 
effects of chemotherapeutic agents are not limited to malignant cells, as the “nonspecific” 
mechanism makes any rapidly proliferating cell a prospective target. 
Paclitaxel and other antimicrotubule agents act upon fundamental organelles 
responsible for cellular division, transport, and signaling (Lee & Harris, 2008). The 
contrasting minus and plus end caps that compose microtubules govern the processes of 
treadmilling and dynamic instability (Nogales, 2001).  
The success of antimicrotubule taxanes is based on the suppression of 
treadmilling and dynamic instability. As the drug binds to the microtubules, mitotic arrest 
is imminent (Lee & Harris, 2008). Loss of microtubule functionality serves as a conduit 
for malignant cell malfunction and demise. Varied treatment modalities can ultimately 
compromise the integrity of healthy tissue as evidenced by the corrosive toxicities 
associated with failing somatic systems.  
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Antineoplastics and Toxicity Development 
Anticancer treatments aim to destroy cancer cells while preserving functionality 
of healthy tissue. Yet, physiological alterations are not limited to malignant cells and the 
consequential toxicities reflect a collective cellular disruption. The severity of side effects 
is based on treatment modality, dosage, and patient tolerance (ACS, 2010).  Quantitative 
analysis, via Nadir, is common practice for hematological evaluation. The value of the 
subjective perceptions should not be negated, however, as they afford relevant 
information in regard to patient response to and tolerance of a particular treatment (Lucia 
et al., 2003). Psychological perceptions of fatigue and depression often mask the primary 
cellular disturbance.  
The impairment of somatic processes emerges as acute or chronic effects 
(Schneider et al., 2003). Acute side effects are characteristic of somatic tissue that relies 
on rapid self-renewal. Because radiation-induced apoptosis occurs during mitotic 
division, cell loss is amplified in tissues with rapid turnover (e.g., skin and mucosal 
surfaces). Proliferation is heightened in response to the treatment-induced cell loss in an 
effort to stabilize mitotic/apoptotic pathways. The immediate effects of radiation 
typically resolve within 1 to 2 weeks of treatment completion (Vargo, Smith & 
Stubblefield, 2008). Acute responses not well-tolerated have potential to progress into 
chronic effects. 
Many antitumor therapies demonstrate cumulative effects over time. While this 
characteristic facilitates constructive eradication of disease, it also augments the severity 
and extent of toxicities. Chronic toxicities gradually develop over the course of treatment 
and endure after completion, giving way to lingering complaints of sustained fatigue, 
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neuropathy, etc. The adverse effects of chemotherapy reflect the nature of its systemic 
drug action. While toxicities develop throughout somatic systems, local skin reactions at 
the injection site are common. Irritants induce a transitory inflammation within the vein 
of administration, subsiding shortly thereafter. Symptoms of tenderness, warmth, and 
redness are indicative of the local response (The Scott Hamilton CARES Initiative 
[CARES], 2005). 
Myelosuppression, a prominent side effect paralleled in chemotherapy and 
radiation, has serious consequences on the functionality of the immune system (Schneider 
et al., 2003). The rapid cellular turnover of hematopoietic tissue makes bone marrow a 
primary target for chemotherapeutic-induced toxicities (Dimeo, 2001). Ultimately, 
declines in red and white blood cells disrupt aerobic metabolism and immunocompetence 
(Nieman, 2003).   
Moreover, low levels of neutrophils (neutropenia) compromise the ability to 
combat pathogenic invasion, piloting the development of flu-like symptoms, weakness, 
and fatigue. Decrements in blood cells and impaired pathogenic defense are 
noncumulative. A conventional 3-week dosing schedule is based on the standard recovery 
from neutropenia within 15-21 days of administration (Vargo et al., 2008). 
Specific drug interactions augment myelosuppressive toxicities; administration of 
cisplatin prior to paclitaxel leads to a 33% reduction in paclitaxel clearance from plasma 
(Wilkes & Barton-Burke, 2008). Accordingly, clinicians administer paclitaxel prior to 
the platinum analog, cisplatin. Adjustments in dosing schedule controls for a portion of 
side effect severity.  
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A loss of bone marrow functionality also facilitates anemic conditions. Low levels 
of hematocrit and hemoglobin compromise the oxygen-carrying capacity. Chemotherapy-
induced anemia is related to an impairment of tissue perfusion (Vargo et al., 2008). 
Compensatory changes are apparent in the form of reduced cardiopulmonary status (e.g., 
maximal oxygen uptake). Reduced blood oxygenation elicits an impairment of oxygen 
utilization for ATP synthesis. As a result, energy is obtained through less-efficient 
anaerobic pathways. Overwhelmed aerobic transport systems perpetuate complaints of 
fatigue and weakness during low-intensity activities associated with daily living.  
Energy and strength deficits are further amplified through gastrointestinal 
toxicity-derived malnutrition. Nutrient deficiencies, arising from reduced absorptive 
capacity, reflect energy balance disruption. The acute side effects of chemotherapy, loss 
of appetite, vomiting, and nausea, drive this process.  Compromised intestinal absorption, 
due to stenosis, ulceration, and fibrosis, can provoke depressed levels of essential 
elements such as magnesium, calcium, and sodium. As a result, secondary 
nephrotoxicities can progress from impaired renal function.  
Chemotherapy stimulates a wide array of neurotoxicities within the central 
nervous system. Many platinum analogs elicit sensory nerve damage; the cultivation of 
peripheral neuropathy arises from heavy metal accumulation within the neuron cell body. 
Ataxia and weakness are manifest immediately following treatment, progressing into 
severe sensory deficits over the course of treatment (Wilkes & Barton-Burke, 2008).  
Distractibility, memory loss, and the inability to multitask typify only some of the 
cognitive impairments resulting from chemotherapy; the collective cognitive impairments 
are often termed, “chemobrain” (Chen et al., 2007). Vestibular setbacks in coordination 
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and balance reveal further impairment of neural control. Such perturbations within the 
central nervous system are etiological in the genesis of cancer-related fatigue (Nerenz, 
Leventhal & Love, 1982). 
Mucositis, ulceration, and related tissue damage evidence chemotherapy-induced 
alteration to mucosal membranes throughout the body. Symptomatic of pulmonary 
fibrosis, dyspnea develops due to the administration of various alkylating agents. 
Pulmonary toxicities reflect damage sustained by microscopic alveoli and transpire as 
inflammation and diminished tissue compliance (Riverside Regional Medical Center 
[RRMC], 2007).  
Potent vesicants, anthracyclines cause severe tissue necrosis when extravasated 
outside of the vein (CARES, 2005). Moreover, anthracycline therapy elicits direct 
damage to cardiac tissue. Acute cardiotoxicities emerge as disruptions in EKG waves 
during and/or immediately following administration. The cumulative nature of cytostatic 
agents augments the threat of late cardiomyopathies and tachycardia (Ross, 1972; 
Yahalom & Portlock, 2008). 
Though by means of disparate mechanisms, radiotherapy elicits several analogous 
toxicities with chemotherapy. The extent to which adverse effects develop is dependent 
upon the total radiation administered as well as length of exposure and number of 
sessions. The development of toxicities is often dictated by tumor location and associated 
irradiation target area (Khan, 2003).  
A spectrum of cardiovascular complications is associated with mediastinal 
irradiation and incidental cardiac damage. Pericarditis, inflammation of the sac enclosing 
the heart, is a common complication following radiotherapy to the chest (Adams et al., 
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2003). With diminished tissue capillarization within the target area, blood perfusion and 
oxygen delivery become compromised. Radiotherapy-induced fibrosis can alter the 
ventilation-perfusion ratio, eliciting inflammatory distress in the form of pneumonitis 
(RRMC, 2007).  
There is a prevalence of skin reactions of the irradiation target area. Localized 
lesions and infections may develop following treatment. Edema, hemorrhaging, and 
inflammation of musculoskeletal and connective tissues cause myofibril disruption and 
progress deficits in muscle integrity and force production (Schneider et al., 2003).  
The risk of second neoplasms following irradiation is a principal concern shared 
by clinicians and patients alike. Such news can be devastating, having severe implications 
on psychological well-being (Bioce, 2009, March). Despite its frequent therapeutic use 
and established efficacy, a growing research base supports the potential of successive 
malignancy development. Lethal dose radiotherapy induces effective cell kill kinetics; 
yet, the administration of sublethal radiation can have tumor promoting effects (Kumar et 
al., 2009). Moreover, when administered over prolonged periods of time, sublethal dosing 
can elicit effects similar to those seen in atomic bomb survivors (Thompson et al., 1994).  
Kumar et al. (2009) demonstrated that a person‟s relative risk (RR) of developing 
a second neoplasm increases linearly with time since exposure. With latency periods of 
13-18, 24-29, and >30 years since initial exposure, a person‟s RR is augmented 25%, 
47%, and 123%, respectively. The absolute risk of radiation exposure-induced cancers is 
1 in 74 people. Not surprisingly, second cancers predominately develop within the field 
of initial exposure. Clinicians often suggest that patients receiving radiotherapy attend 
counseling to psychologically prepare for the prospective late effects associated with 
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primary treatment. The debilitating effects of treatment become more pronounced as 
toxicities impinge on multiple body systems. Curative therapies, irradiation and 
chemotherapy, elicit toxicities in a broad scope of body systems and severity can be 
further amplified on the basis of premorbid conditions, age, treatment modality, etc. 
(Schmitz et al., 2010). Collective toxicities foster fatigue and psychological distress in the 
form of depression and anxiety (Speck et al., 2009).  
When compounded, these issues compromise patients‟ QoL (Beesley et al., 2008). 
Due to the multifactorial origin of cancer-related fatigue it is not feasible to ascertain a 
distinct cause (Lucia et al., 2003). The accrual of toxicities over the course of treatment 
advances the destructive side effects; severity of fatigue can be paradoxically amplified 
through sedentary habits due to catabolism and waning functional capacity (Dimeo, 
2001).  
Cancer-Associated Oxidative Stress 
Critical in a multitude of life processes, adequate supplies of oxygen bring about 
inherent physiological benefits, but, conversely, have the capacity to yield destructive by-
products (e.g., free radicals), inducing a state of oxidative stress (Loft & Poulsen, 1996). 
It has been postulated that oxidative stress is implicated with both the malignant 
phenotype and pathogenesis of cancer (Loft & Poulsen, 1996; Toyokuni, Okamoto, 
Yodoi & Hiai, 1995). Oxidative stress refers to a state in which the generation of free 
radicals exceeds the capacities of the body‟s antioxidant (AOX) defense system (Oberley, 
2001). Free radicals refer to reactive oxygen species (ROS), which educe both deleterious 
and favorable effects in biological systems (Valko et al., 2006). A byproduct of 
respiration, as well as various other biochemical reactions, ROS action depends on the 
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intricate regulation of the AOX system. With appropriate management, ROS maintain a 
breadth of physiological processes, including signal transduction and regulation of 
mitochondrial enzyme activity (Toyokuni et al., 1995). 
The characteristic volatility of ROS molecules demands precise control. It is the 
unpaired electrons of these molecules that provoke a considerable degree of reactivity in 
ROS. As ROS “pull” electrons from surrounding biomolecules (e.g., DNA, protein, 
lipids) to fill an incomplete valence, new free radicals are formed, propagating a chain 
reaction (Valko et al., 2006). A toxic scenario can develop through depressed AOX levels 
due to aging, cancer, ischemia/reperfusion injury, etc., along with sustained production of 
ROS (Valko et al., 2006). If the noxious effects of ROS cannot be managed, destruction 
as per oxidative stress is imminent. 
Oxidative stress reflects excessive free radical disruption on biological molecules. 
Nucleic acid damage/alteration, protein degradation, and peroxidation of lipid 
membranes educe dysfunction throughout somatic tissue. Base pair transversions of the 
DNA helix induce alteration to genetic framework, which may be fundamental in 
oxidative stress-related oncogenesis (Loft & Poulsen, 1996). 
Patients receiving anticancer treatments experience a breadth of deleterious 
toxicities. Oxidative stress serves as one of the primary mechanisms by which 
chemotherapy and radiation induce damage in nontargeted tissue (Chen et al., 2007). The 
administration of platinum-based drugs and alkylating agents has a well-recognized 
association with oxidative stress-mediated damage of healthy tissue. Moreover, according 
to the FDA, 56 of the 132 approved antitumor agents currently used in cancer treatment 
are implicated in oxidative stress (Johnson, Williams & Pazdur, 2003).  
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Treatment-related increases in ROS induce protein damage through the 
upregulation of the ubiquitin-proteosome pathway (Laviano, Meguid, Preziosa & Fanelli, 
2007). This degradation of amino acids can ultimately lead to cachexia of skeletal 
muscle, a common side effect of cancer treatment (Valko et al., 2006). Increased ROS 
production leads to the compromise of contractile function and an alteration of 
mechanisms controlling force development (Toyokuni et al., 1995). Strength deficits 
related to oxidative stress-induced cachexia can be propagated as patients reduce physical 
activity and seek periods of rest (Lucia et al., 2003).  
While the origin of cognitive declines in the central nervous system remain 
somewhat elusive, emerging research supports the mechanistic involvement of oxidative 
stress (Chen et al., 2007). ATP-dependent transporters at the blood-brain barrier (BBB) 
prevent the free movement of substances into certain areas of the brain.  
The proposed mechanism of ROS-induced damage relies on the unrestricted 
movement of a particular cytokine across the BBB (Ehrman et al., 2003). Following the 
administration of chemotherapy, circulating tumor necrosis factor alpha (TNF-α) crosses 
the BBB, triggering the local production of this cytokine in the brain. TNF-α, in turn, 
induces nitric oxide synthase, responsible for the generation of RNS and subsequent 
cognitive toxicities (Abd & El-Sawalhi, 2004). 
Of paramount concern, cardiotoxicities can significantly compromise the integrity 
of the heart. The mitochondria-dense composition (approx. 40% cardiomyocyte volume) 
of cardiac tissue makes the heart especially vulnerable to oxidative stress. Due to the 
“leakage” of electrons from the electron transport chain (ETC), mitochondria serve as a 
primary site for ROS production. Induced disruption of normal metabolic processes 
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augments the threat of late cardiomyopathies and tachycardia (Ross, 1972; Yahalom & 
Portlock, 2008). 
The theory of oxidative stress-induced oncogenesis continues to gain support, as 
researchers begin to shed light upon the proposed mechanisms (Loft & Poulsen, 1996). 
An association between anticancer treatment and oxidative stress is well evidenced in the 
literature (Oberley, 2001). Accordingly, the evolution and pathenogenesis of treatment-
related toxicities are attributable, in part, to augmented ROS activity. With an 
understanding of the mechanisms involved in toxicity development, research efforts 
focus on potential approaches to ameliorate ROS-related toxicities. 
AOX mechanisms generally counteract ROS production, maintaining homeostasis 
within these parallel, yet diametrically opposed, pathways. AOX defense is often 
compromised in those individuals combatting chronic medical conditions (e.g., cancer, 
hypertension, muscular dystrophy, etc.). To protect against free radical damage of healthy 
tissue, patients are frequently encouraged to augment AOX intake.  
According to D‟Andrea (2005), advice to seek AOX supplementation is 
convoluted in cancer patients receiving radiotherapy, suggesting that “supplements do 
more harm than good”. Because ionizing radiation relies on free radical generation as a 
means for cancer cell destruction, AOX supplementation may reduce the efficacy of 
therapy. Furthermore, it‟s been suggested that antioxidants may collectively protect 
healthy and malignant cells.  
A recent publication by Ross (2010) challenges conclusions drawn by D‟Andrea 
(2005). In an attempt to redress the stance taken on AOX supplementation in cancer 
survivors, the original work is described as a “selective and distorted report”. Misleading, 
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over simplistic conclusions are attributed to premeditated research outcomes. Scientific 
fallacy is indicated by the use of research that neither demonstrates objective 
improvement, nor proposed harm in consequence of AOX ingestion. With only a brief 
discussion of two non-enzymatic vitamins (e.g., Vitamin E and C), the article lacks 
conclusive evidence to recommend the blanket rejection of AOX supplementation in 
patients receiving cytotoxic therapy.  
Due to a lack of explicate guidelines, the American Cancer Society does not 
currently recommend heightened AOX intake for those patients receiving cytotoxics, as 
many dietary supplements (e.g., daily multi-vitamin) already contain levels of 
antioxidants above the recommended daily intake (Doyle et al., 2006). The effects of 
specific antioxidant types/dosing on various types of cancer require further elucidation. 
Until agreement is met in regard to AOX supplementation, the most probable benefits 
will be achieved through a balanced diet, consisting of approximately 100% of daily 
values of micronutrients (Doyle et al., 2006). 
There is a growing body of research to support exercise training as a potential 
strategy in the management of ROS-induced toxicities. Following a single bout of 
exercise, a transient upregulation of total antioxidant capacity is demonstrated by acute 
increases in enzymatic AOX, superoxide dismutase (SOD), glutathione peroxidase 
(GPX), and catalase (CAT). In order to achieve enduring AOX enhancement, more 
chronic stimulation (e.g., exercise training) may be necessary (Finaud, Lac & Filaire, 
2006). Paradoxical to the proposed benefits of exercise, contracting skeletal muscle also 
generates free radicals through a transient amplification of oxygen flux within the 
mitochondria and consequential electron leakage (Clanton, Zuo & Klawitter, 1999).  
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High levels of free radicals due to prolonged or intense exercise lead to the 
oxidative damage of cellular constituents (Powers & Jackson, 2008). Yet, a low-to-
moderate production of oxidants serves various cellular regulatory roles. According to 
Finaud et al. (2006), positive adaptations of AOX pathways lead to less oxidative stress 
following moderate intensity exercise training.  
Conversely, the accumulation of intense exercise may trigger free radical 
generation and consequential cellular damage and injury. To ensure attainment of 
proposed benefits demands an understanding of training principles (e.g., frequency, 
intensity, duration, and progression) to establish exercise dose. Moreover, to establish 
appropriate prescriptive exercise for cancer survivors, exercise parameters must be 
understood with respect to this clinical population (Schneider et al., 2003). 
Exercise induces transient but significant changes in immune response, which 
could have severe implications for patients undergoing anticancer treatment due to pre-
existing immunodepression. The J-Curve Model illustrates the relationship between 
exercise dose and immune function (Nieman, 1994). Notable benefits of moderate 
intensity training are evidenced by the preservation of AOX status, which supports 
immune cell (e.g., T-cells, NK cells) functionality (Gleeson, 2007; Schneider et al., 
2003).  
ROS-related perturbations of protein metabolism evolve during and following 
treatment, leading to skeletal muscle wasting (e.g., cachexia), which is perpetuated by 
reduced physical activity (Al-Majid & Walters, 2008). Circulating ROS disrupt cytokine 
signaling, which promotes protein degradation through ubiquitin-proteosome pathways 
(Laviano et al., 2007). Cancer-related cachexia is associated with augmented levels of 
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malondiadehyde, a marker of phospholipid peroxidation and total body oxidative stress. 
The degenerative loss of muscle mass and strength associated with sarcopenia is 
attributed to analogous etiological mechanisms (Meng & Ju, 2010). Alleviation of 
cancer-related cachexia through exercise training demands further clarification of AOX 
mechanisms. 
Based on the research of Fisher-Wellman, Bell and Bloomer (2009), exercise 
training serves as a remedial approach in the attenuation of oxidative stress within 
various chronic conditions. The impact of exercise has been well established in an array 
of chronic diseases, yet there is a deficit of research investigating the effects of exercise 
on AOX/ROS status specifically in the cancer population.  
In patients of coronary heart disease and conjunctive heart failure, the 
upregulation of AOX defense following exercise training is evidenced by heightened 
activity of enzymatic antioxidants (e.g., SOD, GXP, and CAT) and a reduces lipid 
peroxidation of cellular membranes (Linke, Adams & Schulze, 2005; Leaf, Kleinman, 
Hamilton & Deitrick, 1999). Similar findings have been established in diabetic 
populations and patients with cardiovascular disease (Fisher-Wellman et al., 2009).  
At this point, one animal-model study has investigated the effects of training in 
attenuating treatment toxicities; conclusions supported exercise as an amelioration 
approach in tumor-bearing mice (Kanter, Hamlin, Unverferth, Davis & Merola, 1985). 
Kanter et al. (1985) assessed the effects of a 21-week swim intervention on AOX 
enzymes and cardiotoxicity in mice receiving doxorubicin (DOX). Mice were 
randomized into either a swim-trained or sedentary control group; all mice received 
intravenous DOX biweekly over the course of the study. Results indicated severe 
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cardiotoxicity in sedentary drug-treated mice. In comparison, swim-trained animals 
receiving the same DOX dosage revealed attenuated damage. Measured at 9 and 21 
weeks, concentrations of SOD, GXP, and CAT in the liver, heart, and blood were all 
significantly elevated in trained animals (p<0.01), demonstrating an upregulation of AOX 
defense. 
ROS-associated toxicities develop during treatment and, at times, progress long 
after completion; the noxious effects can ultimately compromise various dimensions of 
patients‟ lives. It has been proposed that exercise may attenuate toxicity through an 
upregulation of AOX enzymes. Augmented AOX activity enhances the body‟s capacity 
to combat free radicals and recover from inflicted damage. While other chronic diseases 
indicate a range of benefits relating to habitual exercise, additional research is necessary 
before claims can be extrapolated to cancer. 
Exercise Training and Attenuation of Treatment-Related Toxicities 
The projected 5-year survival rate across all cancers and disease stages has 
climbed to 66% (ACS, 2009a). Improved prognosis and survivorship now demand a shift 
in research efforts. Now regarded as a potential primary, secondary, and adjuvant 
treatment, exercise boasts restorative properties for an array of toxicities, enhancing the 
quality and quantity of life (Courneya, 2003; Speck et al., 2009).  
In spite of the recognized prognostic and therapeutic value, cardiopulmonary 
exercise testing in the field of oncology has been limited, as skeptics deliberate upon the 
safety and practicability in this clinical population (Jones et al., 2007). An investigation 
performed by Jones (2010) reveals exercise testing as feasible and appropriate in cancer 
populations when symptom-limited protocols account for any contraindications. 
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Advantageous to the clinical oncologist, exercise testing allows for an objective 
evaluation of functional capacity to provide an array of prognostic and therapeutic 
information pertaining to disease management. 
Exercise interventions evidence reduced fatigue and enhanced QoL and functional 
capacity (Burnham & Wilcox, 2002; Schneider et al., 2007). Given the multitude of 
physiologic and psychological effects, current research advocates regular physical 
activity as a lifestyle change to enhance the health status of cancer survivors (Lucia et al., 
2003; U.S. Department of Health and Human Services, 2008).  
The effect of individualized exercise on cancer-related parameters, fatigue, QoL, 
and functional capacity, remains central to current investigation. Grueling treatment 
regimens may be curative over time but at the expense of patients‟ physical capacity and 
psychological and cognitive functioning. The most frequently reported symptom, cancer-
related fatigue, pervades and intensifies as treatment continues and ultimately 
compromises QoL and survivability (Durak, Lilly & Hackworth, 1999; Visovsky & 
Dvorak, 2005).  
Early approaches addressing somatic perceptions of fatigue were empiric, leading 
to self-perpetuated symptomology. Recommendations to reduce physical activity 
augment catabolic pathways, inducing acute muscle deconditioning and cachexia. While 
many etiological mechanisms exist to explain pathologic fatigue, it is the metabolic 
distress due to inactivity and treatment-induced alteration of energetic pathways that 
bring about the customary lack of energy in performing everyday tasks (Dimeo, 2001; 
Dimeo, Schwartz, Wesel, Voigt & Thiel, 2008). 
38 
 
 
 
Conclusions drawn from a systematic review by Smets et al. (1993) depict a wide 
ranging prevalence of fatigue, varying by cancer site, disease stage, and treatment 
modality. As a population, irrespective of the abovementioned characteristics, fatigue 
affects approximately 70% of all patients, and remains the symptom most frequently 
reported (Visovsky & Dvorak, 2005; Dimeo, 2001). A multidimensional etiology makes 
alleviation of cancer-related fatigue complex (Smets et al., 1993). 
Dimeo et al. (2008) studied the effects of a 3-week combined exercise 
intervention in 32 cancer patients, post high-dose chemotherapy. The subject population 
was consisted of mixed diagnoses including solid tumors (e.g., breast, bladder, prostate, 
testicle, and cervix), Hodgkin‟s disease, non-Hodgkin‟s lymphoma, multiple myeloma, 
and myelodysplastic syndrome. Subjects performed treadmill walking (80±5% HRR) and 
resistance exercises of large muscle groups. Significant improvements in functional status 
were documented as per the workload achieved at anaerobic threshold (p < 0.0001). 
Moreover, global fatigue scores decreased by 25%, indicative of reduced psychological 
distress. Enhanced functional capacity was associated with reductions in complaints of 
fatigue during normal daily activities, owing to improvement in blood oxygen transport 
as well as capillary and mitochondrial density (Lucia et al., 2003; Dimeo et al., 2008). 
Results are consistent with those found in a 1997 pilot study, in which the 
correlative relationship between physical deficits and psychological distress was assessed 
in 78 cancer patients of solid tumors or hematological malignancies (Dimeo et al., 1997). 
Subjects with impaired physical performance indicated significantly higher scores for 
mental distress (p < 0.005).  
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In addition, a strong correlation between fatigue and depression (r = 0.68) further 
elucidates upon emergence patterns of psychological impairments, which could provide 
insight for rehabilitative strategies (Dimeo et al., 1997, 2008). With up to 30% of cancer 
patients complaining of persistent adverse effects long after treatment, novel remedial 
approaches are welcome (Berglund et al., 1991). 
Exercise augments the work performed by the cardiac and respiratory systems. As 
a result, adaptive changes occur in plasma volume, lung ventilation and perfusion, and 
oxidative enzyme concentration. Such adaptations elicit ATP production through more 
energy efficient oxidative pathways due to improvements in oxygen carrying-capacity, 
transport and delivery to working muscles. According to Schneider et al. (2003), the 
physiological benefits of exercise oppose toxicities generated during antitumor treatment. 
This „mirror effect‟ minimizes cancer related fatigue through improved cardiovascular 
efficiency. 
The manifestation and progression of fatigue during treatment highlights the 
cumulative nature of treatment modalities. Because the intensity of fatigue can endure 
long after cessation of treatment, research efforts are now evaluating rehabilitative 
exercise programs undertaken amid treatment, in order to determine if persistent effects 
are better eluded. Adamsen et al. (2006) designed a multi-modal exercise program to 
investigate its impact within a sample of 66 cancer patients undergoing cytostatic 
treatment. Because there is evidence to support that fatigue and physical impairment 
develop irrespective of cancer type, subject population was inclusive, comprising six 
different hematological malignancies and thirteen types of solid (oncological) tumors 
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(Smets et al., 1993; Lucia et al., 2003). Few studies have been carried out to allow 
generalizability across comprehensive cancer sites. 
 The 6-week study consisted of resistance and cardiovascular training, as well as 
relaxation and body awareness training. High-intensity exercises, resistance training and 
cycle ergometry, were performed at 85-95% 1RM and 60-100% heart rate max, 
respectively. Low-intensity exercises focused on balance, coordination, tension reduction 
and relaxation. Nonconsecutive days were allotted between high- and low-intensity 
workouts.  
In order to assess the effects of training, two physiological tests (1RM & 
VO2max) and two psychological questionnaires (MOS SF-36 & QLQ-C30) were 
conducted at baseline and again after six weeks of training. Upon completion, there were 
significant improvements in aerobic capacity (p < 0.001). For all subjects, the average 
percent change in maximal oxygen consumption was +16%. Augmented strength gains 
led to significant improvements in leg press (+46%), chest press (+41%), and lat pull 
down (+36%) resistance exercises.  
Along with augmented functional capacity, questionnaire data revealed significant 
improvement in the level of vitality (p = 0.002), perceptions of health (p = 0.009), and 
alleviation of fatigue (p = 0.008). With regards to the improvements achieved in physical 
and psychological status, no significant difference existed between oncological and 
hematological patients. This study encourages participation in exercise for those 
receiving adjuvant therapies, as it manages the treatment-related symptoms, enhancing 
psychological well-being and physiological capacity. 
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In agreement with Adamsen et al. (2006), Courneya et al. (2007) evaluated the 
effects of exercise in a sample of breast cancer patients receiving adjuvant chemotherapy. 
Divergent from universal participation in multimodal exercise, subjects were randomly 
assigned to one of three groups: usual care (UC), supervised resistance exercise (RET), or 
supervised aerobic exercise (AET). This three-armed, randomized trial sought to 
determine if a particular exercise component (resistance vs. aerobic) led to more 
significant beneficial effects in patients receiving cytostatic treatment.  
The relative dose intensities (RDI) were higher in both exercise groups (RET, 
89%; AET, 87%), when compared to subjects receiving standard care (UC, 84%). 
Findings indicate that the true dosing schedule administered to the exercise groups was 
closer to the pre-established regimen. Ultimately, reductions in RDI, because of delays in 
delivery or reduced dose, can have implications on disease prognosis (ACS, 2010; Dizon, 
2010).  
When compared to those receiving standard care, both exercise groups showed 
improvement of psychological parameters: QoL, depression, self-esteem and anxiety. The 
alteration of physiological parameters is specific to modality of exercise performed. 
Resistance exercise led to enhanced physical functioning related to muscular strength 
(p<0.001), and lean body mass (p=0.015), whereas aerobic exercise improved the 
outcome measures of aerobic fitness (p=0.006) and percent body fat (p=0.076). 
Researchers advocate a „whole body‟ approach of exercise programming, employing 
resistance and aerobic components for more complete benefits (Courneya et al., 2007; 
Schneider et al., 2003).  
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Moderate intensity, multidimensional training is a recurrent design employed in 
oncology studies. Yet, investigation of either aerobic exercise or resistance training has 
revealed related benefits to those found in combined studies (Burnham & Wilcox, 2002). 
The outcome measures common to aerobic exercise studies include aerobic capacity, 
depression, anxiety, QoL, fatigue, and emotional distress (Visovsky & Dvorak, 2005).  
Dimeo, Rumberger & Keul (1998) suggested aerobic exercise as a potential 
therapeutic intervention for cancer-related fatigue. Subjects (n=5) in this study performed 
treadmill walking each day for six weeks to determine the effects on fatigue and 
functional status. The training speed employed corresponded to a lactate concentration of 
3±0.5 mmol•L-1 and was increased with evidenced training adaptation (e.g., reduced 
exercise HR and [LA] < 2.5 mmol•L-1).  
Following reassessment, there was significant improvement in physical 
performance as depicted by training distance/session as well as calculated [LA] and 
submaximal HR at a specified workload. In addition, reductions in subjective fatigue 
scores allowed all subjects to return to normal daily activities without limitations.  
The professed merit of aerobic exercise is evidenced by the heightened physical 
status and attenuated fatigue. The effect of aerobic training on psychologic and 
physiological parameters was also assessed by Durnham and Wilcox (2002), with 
emphasis on variable intensity aerobic exercise. Low- and moderate-intensity exercise, 
distinguished by the percentage of heart rate reserve (HRR), was performed at 25-35% 
HRR and 40-50% HRR, respectively.  
Upon completion of the ten week study, no significant difference in physical 
parameters, aerobic capacity and body fat percentages, existed between the exercise 
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groups; as a result, final analysis was performed on combined exercise groups versus 
controls. Resembling the conclusions drawn by Dimeo et al. (1998), physical functioning 
and QoL status improved (p < 0.001) in the exercise group versus sedentary controls. A 
significant reduction in body fat percentage (p < 0.001) illustrates the benefits related to 
body composition resulting from exercise participation.  
Research suggests that regular physical activity is protective against a host of 
chronic diseases (Nieman, 2003). Specifically, habitual exercise is associated with 
reduced cancer risk, owing to the stabilization of energy balance and circulating hormone 
levels following activity (Fair & Montgomery, 2009). As a primary intervention, exercise 
boasts a 20-40% reduction in cancer incidence (Holmes, Chen, Feskanich, Kroenke & 
Colditz, 2005). 
According to an updated meta-analysis by Speck et al. (2009), the remedial 
properties of exercise for cancer survivors continue to gain interest and support, as the 
volume of literature has more than doubled in the past five years. Exercise as an adjuvant, 
rehabilitative strategy has been recognized as feasible and valuable in supervised settings 
(Schneider et al., 2007; Viscosky & Dvorak, 2005). Moreover, the multitude of 
physiological adaptations attenuates the corrosive toxicities related to treatment. 
Specifically, improved somatic parameters and physical functioning indicate favorable 
health outcomes. Inclusive benefits are attained through individualized regimens, 
involving aerobic and strength components (Jones et al., 2007; Ingram & Visovsky, 
2007).  
Historically, the preponderance of exercise studies has targeted breast cancer 
survivors, making extrapolation to all cancer sites and stages impractical (Courneya et al., 
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1999).  Growing evidence is becoming available to support exercise participation across 
cancer sites (Dimeo et al., 2008; Klika, Callahan & Golik, 2008). In a recent publication, 
Schmitz et al. (2010) outlined current research evaluating the effects of exercise training 
by cancer site. The lack of studies across cancer sites demands that progress be made. 
Currently, efficacy of exercise programming for cancers of the prostate and colon have 
been evaluated in 12 and 4 studies, respectively. Outcomes of exercise interventions for 
hematologic malignancies either treated with hematopoietic stem cell transplantation 
(HSCT) or in the absence of HSCT, have been evaluated in 11 and 4 studies, 
respectively.  
The most prominent deficiency of exercise research is apparent in gynecological 
cancers. While 5 mixed sample studies have included a small proportion of gynecologic 
patients (n=5-15), only one intervention has exclusively assessed this specific population. 
Conclusions drawn from mixed sample studies indicate enhanced psychological 
functioning (e.g., QoL, self-efficacy, and wellbeing), reduced fatigue, and improvements 
in cardiorespiratory fitness following a structured exercise intervention (Berglund, 
Bolund, Gustafsson & Sjoden, 1994; Courneya et al., 2003; Hartvig, Aulin, Wallenberg 
& Wagenius, 2006; Thorsen et al., 2005; van Weert et al., 2005). No specific assumptions 
were made about exercise with regard to cancer type. 
Undertaken by von Gruenigen et al. (2008), the current solitary gynecologic study 
is considered a weight loss intervention, with the primary endpoint of weight change. The 
study sought to assess the effects of a lifestyle intervention in 45 early-stage, overweight 
and obese endometrial cancer survivors. Subjects were randomized to either a 6-month 
lifestyle intervention (LI) or usual care (UC) control group. Parameters to be examined 
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included weight change, physical activity, and dietary intake. Subjects in the LI group 
attended group and individualized counseling sessions with a registered dietician and 
psychologist. Topics discussed in group sessions included weight loss readiness, exercise, 
and portion control.  In regard to exercise, subjects were coached to gradually increase 
walking and other routine physical activities. Progress was monitored via a pedometer.  
Upon completion, changes in body mass for LI and UC were -3.5kg and +1.4kg, 
respectively. Though reduced in LI subjects, caloric intake was not significantly different 
from the control group. Enhanced exercise participation in the LI group was evidenced by 
the increase of 17 MET/week compared to the UC group (p=0.025). Because exercise 
was performed on subjects‟ own accord, measureable effects were limited to changes in 
steps/day, as dictated by the pedometer.  
Thus, it was not possible to quantify time and intensity. Lack of a structured 
exercise intervention and reliance on self-reported exercise participation (Leisure Score 
Index) highlight research gaps. Because weight change served as the primary endpoint, 
with changes in physical activity considered secondary health outcomes, the feasibility 
and effectiveness of this intervention, in regard to exercise effects, is suspect.  
Research investigating the effects of exercise in gynecological cancer survivors is 
scant. Further evidence is needed to validate specific health outcomes (e.g., QoL, fatigue, 
and functional capacity). In addition, the effects of exercise at various time points on the 
cancer continuum should be investigated to determine potential risks and benefits 
(Courneya & Friedenreich, 2007). Secondary conditions such as lymphedema are the 
unfortunate consequence of cancer and its treatment. In view of the complexities 
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associated with lower limb lymphedema and its management, additional research is 
warranted to determine if exercise is feasible and appropriate under such circumstances. 
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CHAPTER III 
METHODOLOGY 
Experimental Design 
 The purpose of this case study is to determine whether an exercise undertaken by 
a late-stage endometrial cancer survivor receiving high-dose chemotherapy is feasible 
and appropriate. More specifically, this in-depth analysis investigates the effects of a 
multimodal exercise intervention on a selection of physiologic and psychological 
parameters. Oxidative stress was also assessed through a hematological assay of reactive 
carbonyl species concentration. Baseline measures were gathered prior to the start of 
exercise, with Nadir blood draws obtained throughout the intervention every third week, 
which was 10 days following a chemotherapy treatment. Initial patient screening was 
conducted, which included the assessment of physical capacity, as per peak aerobic 
capacity (VO2peak) and one repetition maximum (1-RM), and an evaluation of 
psychosocial status (e.g., QoL, depression, and fatigue).  
From results gathered during the assessment, an exercise regimen was designed 
and implemented by a trained Cancer Exercise Specialist at the Rocky Mountain Cancer 
Rehabilitation Institute (RMCRI) at the University of Northern Colorado in Greeley, 
Colorado. At 3- and 6-months, assessment procedures were again performed to track 
progress and modify exercise, if necessary. An hour in length, supervised exercise
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sessions were held on Tuesday, Thursday, and Saturday of each week. It was assumed 
that the subject would not participate in additional exercise beside that indicated by the 
intervention. Each workout incorporated a combination of strength and aerobic 
components. Blood pressure was measured both prior to and upon completion of each 
training session, with heart rate (HR) and ratings of perceived exertion (RPE) measured 
throughout the protocol. Within the exercise logbook, there was allotted spaced to make 
additional notes of progress, perceptions, lab results, etc. 
Participant 
 Due to the nature of case study research, a single subject was recruited for this 
study. The basis for employing case study methodology was to perform a comprehensive 
analysis in an area currently lacking conclusive research. A faculty member at an 
institution for higher education, the female subject was 60 years of age at the start of this 
case study and had given written consent to participate in this study. An irregular Pap test 
in December of 2009 led clinicians to order an endometrial biopsy, which revealed the 
endometrial adenocarcinoma. The tumor was moderately differentiated and 4.9 cm
3
 in 
size with pelvic nodal involvement. There were no para-aortic nodes affected at the time 
of discovery.  
Tumor staging was complicated by a 1994 diagnosis of cervical cancer which, at 
the time, was handled by performing a curative-intent hysterectomy to remove the tumor 
and reduce the chance of recurrence. Oncologists responsible for discovering the most 
recent tumor, however, deemed the primary cancer had been misdiagnosed. What was 
determined cancer of the cervix was, in fact, cancer of the endometrium. At the beginning 
of this investigation, the cancer stage was deemed, „unspecified‟. 
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To make matters more complex, the subject had received a lifetime dose of 
ionizing radiation in 1997 (3 successive days, internal brachytherapy; 25 treatments/5wk, 
external beam) in an effort to treat and cure the primary neoplasm. Radiation treatment 
for the recurrent cancer would likely provoke lethal implications. As a result, the selected 
course of action was 6 conventional chemotherapy treatments of paclitaxel and 
carboplatin through intravenous delivery. The initial assessment and baseline 
hematological analysis were performed a day prior to the first chemotherapy cycle. 
Dosage schedule involved a target AUC of 5.0-7.5 every 3 third week. Sequential 
infusion of paclitaxel then carboplatin effectively disrupts tumor kinetics by means of 
covalent DNA binding, as evidenced by an impediment of tumor growth.  
Preliminary Paperwork 
 The subject was given explicit detail of the study‟s purpose and procedures, as 
outlined in the informed consent, and asked to complete the following pre-screening 
paperwork: cancer history, complete medical history, cardiovascular disease risk 
assessment and lifestyle/activity evaluation. All prescreening paperwork collected from 
the subject was reviewed and verified upon arrival for the initial assessment. From the 
medical and cancer histories, any concurrent comorbidity could be evaluated so as to 
assess possible limitations and considerations relevant to the exercise prescription. The 
subject‟s lifestyle, with regard to activity level, dietary intake, and regular tobacco and 
alcohol use, was illuminated through responses on the lifestyle/activity evaluation. Initial 
values for blood pressure (BP), HR, and oxygen saturation (PO2) were determined. 
Height and weight were measured and recorded, as this information would be necessary 
for completing a portion of the assessment protocols. Any relevant morbidity (coexisting 
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medical conditions, all OTC and Rx medications, etc.) that could potentially be 
contraindicative to participation in this study were assessed prior to the start of exercise.  
Distribution and Interpretation of Psychological Indexes 
 Prior to the initial assessment, along with each reassessment thereafter, the 
following psychological indexes were completed in their entirety: Piper Fatigue Scale, 
Beck Depression Inventory, and Ferrans & Powers Quality of Life Index Cancer Version 
III. Results from the Piper Fatigue Inventory yield a global score, which indicates the 
overall extent of cancer-related fatigue (CRF). Values calculated for behavioral, 
affective, sensory, and cognitive/mood subscales can demonstrate specific dimensions of 
a patient‟s life most afflicted by CRF. Collectively, the 4 subscales compose the 22-item 
inventory. Possible scores for each subscale range from 0 to 10. Total fatigue scores also 
range from 0 to 10 and are computed by determining the average of all subscales. A total 
score of 0 is indicative of a cancer survivor with no perceptions of fatigue. Scores ranging 
from 1-3, 4-6, and 7+ indicate mild, moderate and severe fatigue, respectively (Piper et 
al., 1998). 
   Depression, a common side effect following antineoplastic treatment, was 
assessed using the Beck Depression Inventory. Each of the 21 items on the Beck scale is 
comprised of 4 declarative statements corresponding to values ranging from 0 to 3. 0-
value statements reflect the most extreme negative position. Contrary assertions, valued 
as 3, indicate the most extreme positive statement. Numerical values, 1 and 2, signify 
some degree of neutrality though one end of the spectrum may be favored. Values for all 
22 items are added; scores range from 0 to 63 with 0 indicative of no depression and >40 
reflecting extreme depression (Salkind, 1969).   
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 Utilizing Ferrans & Powers Quality of Life Index Cancer Version III, QoL was 
assessed at baseline, 3-, and 6-months. This 66-question index evaluates a) subject 
satisfaction with and b) importance placed on the following dimensions of inquiry: social, 
psychological, family, and health. This Ferrans & Powers assessment has an impressive 
internal reliability (α=0.95) and validity (r = 0.80). High total scores reflect agreement 
between the satisfaction with and importance placed on each dimension, which ultimately 
corresponds to an appropriate state of well-being (Ferrans & Powers, 1985). 
Assessment of Pulmonary Function  
 Pulmonary function was assessed by means of a Flowmate
TM
 (Spirometrics, Grey, 
ME) spirometer. Predicted normal values were based on the subject‟s physical 
characteristics: height, weight, age, race, and tobacco use. The subject was given detailed 
instructions on performing the test. The rationale and clinical value of spirometry 
analysis were also discussed. In order to be considered a valid assessment of lung 
function, the forced expiratory volume (FEV1) of two consecutively performed tests had 
to be within 0.2 L of each other. If a third maneuver was required and, still, the criterion 
wasn‟t met, results were not interpreted. On the final printout, expected and measured 
values of forced vital capacity (FVC) were also provided, which portrayed the total 
volume of air expired during the maximal forced exhalation effort.  
 Variance between the predicted norm and the measured value was used to identify 
and quantify functional abnormalities; specifically, the ratio FEV1/FVC can detect 
impairments of the respiratory system. Ratios of >0.7 are considered normal; deviations, 
in the form of reduced FVC and total ratio value <0.7, are deemed as restrictive and 
obstructive ventilatory impairments, respectively.  
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Assessment of Muscular Strength 
 Muscular strength was assessed using l-repetition maximum (1-RM) testing 
protocol for the following exercisees: lat pull-down, leg press, chest press, and shoulder 
press. All protocols were carried out using the Cybex® Eagle Single Station Pin 
Selection Series. An expertise in the field of exercise physiology as well as a history as a 
collegiate athlete fostered the subject‟s familiarity with 1-RM testing. For the purpose of 
warming-up musculature, a “very light” weight was selected that could be lifted for 5 to 
10 repetitions. Weight was added in approximately 5 to 10 pounds increments, and 2 
additional sets were performed of 3 to 5 repetitions. With the slow augmentation of 
weight, the load begins to approach that of the first maximal attempt. Two additional sets 
of 1 repetition were performed. Between all lifts, 1 minute rest intervals were allotted, to 
allow sufficient recovery (Warpeha, 2010). Weight was increased in 2.5 lb. intervals until 
failure. The last successful attempt was deemed the 1-RM weight. The warm-up and 
gradual progression was repeated for each exercise.  
Assessment of Cardiorespiratory Fitness 
 The RMCRI treadmill protocol was used to evaluate the subject‟s 
cardiorespiratory fitness (CRF). Adapted in 2010, this treadmill test was designed with 
the cancer survivor in mind, and is to be carried out in this clinical population. All details 
of testing protocol were given to the subject. Contraindications against performing the 
test were considered. With no pre-existing comorbidities of concern, the test was 
initiated. Using the MedGraphics® Diagnostics System and BreezeSuite™ computer 
software, RMCRI protocols were programmed into and stored on the hard drive, allowing 
researchers to monitor vitals (e.g., BP, HR, and RPE) during the test without the added 
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hassle of manually adjusting workloads. Stages were 1 minute in length with intensity 
adjusted as a means of belt speed, incline, or both each successive minute. Stage 1 
walking speed was 1.0 mph, increasing by 0.5 mph until stage 6. Stages 1 through 4 
maintained a constant grade of 0.0%. The first modification to grade was made at stage 5; 
this 2.0% incline was maintained through stage 6. From stage 7 until stage 21 or 
volitional fatigue, grade and belt speed increased 1.0% and 0.1 mph, respectively.  
 HR and PO2 were recorded every minute with BP and RPE recorded every third 
minute until test completion. The stage attained at test termination corresponded with a 
VO2peak based on age, gender, and handrail use. Finally, the CRF classification 
corresponding to the aerobic capacity (mL/kg
-1
/min
-1
) was determined.  
Balance Assessment 
 The modified Clinical Test for Sensory Interaction on Balance (mCTSIB) was 
employed to assess deficits in balance. This test has the capacity to discriminate between 
normal and abnormal balance performance but cannot detect specific patterns of sensory 
dysfunction. Results of mCTSIB testing may elucidate upon the development of 
vestibular setbacks related to cancer treatment. Each phase of this 4-part protocol is 30 
seconds in length. The progression of testing phases includes: 1) eyes open, firm surface 
2) eyes closed, firm surface 3) eyes open, foam pad 4) eyes closed, foam pad. Each stage 
corresponds to a numerical score of 30. Thus, a perfect score of 120/120 indicates that a 
subject maintained his or her balance during the entirety of all 4 stages. Incomplete stages 
are assigned a score of 0. Staggering, requiring spotter assistance, etc serve as grounds 
for test termination. Finally, the total score was calculated and balance classification 
determined. 
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Exercise Intervention: Development and Implementation 
 Outcomes of the initial assessment were used to develop an exercise prescription 
with the primary objective of maintaining physiological and psychological functioning 
while the subject underwent chemotherapy. The secondary endpoint, reactive carbonyl 
derivative response, was assessed to determine if exercise could alleviate oxidative stress- 
related damage. The subject underwent 6 cycles of PC while involved in the study.  
 Supervised training was carried out on 3 non-consecutive days per week for 6 
months. Multidimensional exercise was performed for approximately an hour. Sessions 
consisted of moderate intensity aerobic, strength, and balance components for 25, 30, and 
5 minutes, respectively. Initially, muscular strength exercises consisted of 2 sets of 10 
repetitions, performed at 70-75% of estimated 1-RM. Exercises included:  leg press, leg 
curl, leg extension, chest press, lat-pull down, and shoulder press. All exercises were 
completed on the Cybex® Eagle Single Station Pin Selection Series, just as they had 
been for assessment procedures. Prior to each exercise session, researchers reviewed a 
series of 10 questions to document any changes in medication, health status, 
pain/soreness resulting from previous workout, etc. Responses could highlight a need to 
reduce training intensity.  
 Using the modified 0-10 Borg RPE scale, subject-dictated perceptions of intensity 
were used to adjust the weight when necessary. RPE values <4 were used to increase the 
weight for the next workout; reduced RPE values were indicative of positive training 
adaptations. When appropriate, the progression of augmenting weight occurred in 2.5 
pound increments. The initial target RPE range was 6 to 8, which was used as an 
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indicator of moderate intensity in this study. HR and PO2 data were collected after 
completing both sets of a given exercise, and RPE values were assessed after each set.  
 Due to side effect development 3 to 4 days after the administration of 
chemotherapy, the intensity of training was reduced to 30-35% 1-RM. Repetitions and 
sets were held constant at this reduced percentage of maximum effort. In order to 
attribute physiological changes to the designed intervention, the subject was directed to 
refrain from additional physical activity, apart from normal living, while participating in 
the study.  
Protein Carbonyl Determination & CBC Analysis  
 Blood samples were obtained at the Cancer Center at Northern Colorado Medical 
Center 10 days following each chemotherapy treatment (Nadir). Blood was placed into 
one of two tubes: either a 3 mL purple top tube, indicating the presence of 
ethylenediamine tetraacetic acid (EDTA) or a 5 mL red top tube without the 
anticoagulant. Samples collected at the hospital were placed on ice and returned to the 
biochemistry laboratory at UNC for centrifugation and further analysis. Test tubes were 
brought to room temperature prior to separation to ensure samples were adequately 
thawed. Tubes were spun for 10 minutes at 3,000 revolutions per minute (rpm). Using a 
micropipette, supernatant serum was removed from the sample lacking anticoagulant and 
evenly distributed into two 100 µL snap tubes. Tubes were immediately frozen as -20°C 
for later analysis. Extraction procedures were repeated for the blood sample with EDTA; 
plasma was also stored at -20°C. 
 OxiSelect™ Protein Carbonyl ELISA techniques were carried out for the 
detection and quantification of oxidative stress in collected blood samples (Cell Biolabs, 
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Inc., San Diego, CA). The amount of protein carbonyls in collected samples were 
determined by comparing the absorbance to that of known BSA standards. Methods were 
carried out as specified by the OxiSelect™ product manual; detailed procedures can be 
viewed at www.cellbiolabs.com. Results of complete blood counts (CBC), attained 
during Nadir blood draws, were reviewed and included in the results section. No 
additional analysis was employed for this portion of hematological parameters.  
Statistical Analysis 
Graphical analyses of outcome measures were primarily used to assess trends in 
the data. In some cases, Wilcoxon Signed Ranks was used to determine if significant 
changes had occurred in any of the assessment outcome measures. Statistical analyses 
were performed using GraphPad Prism Version 5 for Windows (GraphPad Software, San 
Diego CA). For all analyses, a p-value of 0.05 was considered statistically significant
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CHAPTER IV 
RESULTS 
Change in Assessment Outcome Measures 
Physical characteristics are presented in Table II. The initial assessment was 
performed on January 20, 2010 with first and second assessments performed at 3 months 
(April 1, 2010) and 6 months (June 25, 2010), respectively. Six cycles of chemotherapy 
were administered over the course of the study. Dates of treatment included January 21, 
February 12, March 5, April 8, April 30, and May 21, 2010. Physical characteristics 
measured at each assessment time point are presented in Table II. Height and leg 
circumferences remained stable over the course of the study, with 7% increases in both 
weight (166 to 178 lb) and BMI (27.6 to 29.6). At the start of this intervention, staging 
criteria for the endometrial adenocarcinoma was unspecified. On June 20, 2010, 
clinicians determined the TNM criteria: T3, N1, and M0. The tumor was staged as IIIC1. 
 
Table 1. Physical Characteristics of Case Study 
Physical Characteristic Baseline 3-Month 6-Month % ∆i-f 
Height (in) 65 65 65 - 
Weight (lb) 166 172 178 +7% 
Body Mass Index (BMI) 27.6 28.6 29.6 +7% 
Thigh Circumference (in) 20 20 20 - 
Lower Leg Circumference (in) 15 16 15 - 
58 
 
Strength and aerobic assessment data are presented in Tables 3 and 4, 
respectively. Wilcoxon Signed Ranks statistical analysis revealed no significant 
difference in the 1-RM weight for any of the strength exercises (p=.25, each). Trends in 
muscular strength are depicted in Figure 1. Between initial and 6-month assessments, 
total gains of 17%, 21%, and 9% were determined for the lat pulldown (95 to 115 lb), 
shoulder press (55 to 70 lb), and leg press (225 to 245 lb), respectively. The weight lifted 
for the chest press decreased approx. 17% between baseline and final assessment time 
points (90 to 75 lb). Collectively, the total percent change in upper and lower body 
strength was +21% and +9%, respectively.  
 
 
 
Table 2. Effects of Exercise Intervention on Muscular Strength  
 
 
Note. All values are presented as weight in pounds (lb) 
 
 
 
 
 
 
 
 
 
 
 
 
Exercise  Baseline 3-Month 6-Month 
Lat Pulldown 95 107.5 115 
Chest Press  90 80 75 
Shoulder Press  55 60 70 
Leg Press  225 235 245 
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Figure 1. Changes in 1-RM from Baseline  
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Cardiorespiratory fitness parameters assessed during the intervention included: 
treadmill (TM) time to volitional fatigue, aerobic capacity (VO2peak), and spirometry 
parameters, forced expiratory volume (FEV1) and forced ventilatory capacity (FVC). As 
evaluated by time to fatigue, performance on the RMCRI Treadmill Test improved 30% 
between initial and final assessments (12.0 to 14.0 min). Directly related to TM time, 
VO2peak improved 16% between the baseline and 6-month assessments (23.0 to 27.3 
mL/kg
-1
/min
-1
). Between the baseline and 6-month assessments, FVC and FVC1, 
evidenced declines of 9% and 10%, respectively.  
 
 
 
Table 3. Effects of Exercise Intervention on Cardiorespiratory Fitness  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Baseline 3-Month 6-Month 
TM Time (min) 12.0 13.3 14.0 
VO2peak (mL/kg
-1
/min
-1
)  23.0  26.2 27.3 
FEV1 (L/min
-1
) 3.43 3.24 3.07 
FVC (L/min
-1
)  4.11 4.01 3.75 
61 
 
 
 
2.5
3.0
3.5
4.0
4.5
5.0
2.5
3.0
3.5
4.0
4.5
5.0
FEV1
FVC
Baseline 3-Month 6-Month
-2%
-10%
-6%
-9%
F
E
V
1
(m
L
/k
g
-1
/m
in
-1
) FV
C
 (m
L
/k
g
-1/m
in
-1)
 
 
  
 
Figure 2. Effects of Exercise Intervention on Spirometry Variables  
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 Figure 3. Change in Aerobic Capacity and Time to Fatigue  
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Total Piper fatigue, as well as subscale scores, can be found in Table 4. Wilcoxon 
Signed Ranks revealed no significant differences in total fatigue scores (p=.17), though 
scores increased 97% between the baseline and 3-month assessment. Changes in fatigue 
subscales (e.g., cognitive, sensory, affective, and behavioral) are depicted in Figure 4. A 
nonparametric Friedman Test indicated significant changes in affective and sensory 
fatigue subscales between the baseline and 3-month assessment (p=.05). No change in 
psychologic parameter, QoL, occurred over the course of the intervention.  
 
 
Table 4. Effects of Exercise Intervention on Patient-Rated Psychologic Variables  
 
Variable Baseline  3-Month 6-Month 
QoL 
 
Total Fatigue  
 
Piper Subscales 
25 
 
.04 
25 
 
1.2 
25 
 
1.2 
 
Behavioral 0 7 3 
 Affective 0 1 12* 
 Sensory 1 6 10* 
 Cognitive 0 2 3 
 
Note. Piper fatigue scores range from 0 (no fatigue) to 10 (severe fatigue); *p=.05, 
significant difference between baseline and 3-month assessments   
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 Figure 4. Changes in Piper Subscales with Exercise Intervention 
 
 
 
 
Changes in Training Load 
Training mode, duration of training session, RPE, and HRR, were prescribed and 
implemented from January 23, 2010 to June 17, 2010 (141 d). For the purposes of this 
study, the 141-day span was divided into two 3-month Phases, marked by the second 
assessment date. Prescribed training intensities for aerobic and strength components are 
portrayed in Table 5. Initial intensities set forth for strength and aerobic components were 
70-75% 1-RM and 55-65% HRR, respectively. Training intensity bounds were adjusted 
as necessary throughout the study.  
One complication occurred during the intervention. On February 16, 2010, 
extreme hypotension led to the following side effects: dizziness, light-headedness and 
weakness. The adverse effects were most likely propagated by the case study‟s 
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prescription blood pressure medication, Lisinopril. To avoid such events in the future, the 
training load was reduced to 30-35% 1-RM and 30-35% HRR for strength and aerobic 
components, respectively, the first week following treatment (Nadir training). For all 
other training sessions (Standard training), intensities were maintained. 
Following the April 1, 2010 reassessment, 1-RM percentages were reduced 
approx. 14% for strength exercises (70-75 to 60-65% 1-RM). Phase II HRR was 
increased 12% (60-70% HRR). Training intensities employed during Nadir were 
augmented approximately 30% for both strength and aerobic components to address 
complaints of a “lack in difficulty”. Modifications made to training intensities over the 
course of the study are presented in Figure 5. 
 
 
Table 5. Strength and Aerobic Training Loads 
 
 
Note. Phases I and II were undertaken in the time frame of this study; intensities set forth 
for Phase III depict projected training loads, had the study protocol continued. 
 
 
  
 
 
 
Component 
Phase I  Phase II  Phase III 
Standard Nadir Standard Nadir Standard Nadir 
 
Strength (%1-RM) 
 
70-75 
 
30-35 
  
60-65 
 
45-50 
  
50-55 
 
45-50 
 
Aerobic (% HRR) 
 
55-65 
 
30-35 
  
60-70 
 
40-50 
  
60-70 
 
40-50 
 
65 
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70
80
Strength
Strength
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Aerobic
Standard Training Load
Nadir Training Load
Phase I Phase II Phase III*
 
 
Note. Phase III training loads were designed from 6-month  
assessment data. Proposed intensities would have been employed 
had the study continued on. 
 
 
Figure 5. Changes in Imposed Training Loads over Time 
 
 
 
 
Changes in Subjective Parameters 
Table 6 presents RPE data compiled for Phases I and II of standard and Nadir 
training. The prescribed RPE range for each training phase can be found in Table 6 as 
well. As indicated in Figure 6, RPE scores did not differ significantly between standard 
training Phases I and II (p=0.25). However, scores differed significantly for Nadir 
training Phases I and II (p=.003). Significant variation from the prescribed RPE range 
was detected in Phase I Nadir training (p=.008). Comprehensive tables of all weekly RPE 
66 
 
scores are presented in APPENDIX A. All relevant subjective feedback was documented 
over the course of the study and recorded in RMCRI charting sheets. Charting sheets can 
be found in their entirety in APPENDIX B. Notes included: perceptions of exercise 
intensity, complaints of pain/lack of energy, results from medical scans/ prognostic 
changes, treatment side effects, etc. Charting sheets served as a subjective index to 
monitor psychological distress.  
 
 
 
 
Table 6. Effects of Exercise Intervention on RPE Scores  
  
 
Note. Values are means ± standard error; ** p=.008, significant difference from 
prescribed RPE range  
 
 
 
 
 
Component 
Phase I  Phase II 
  
Standard Nadir  Standard Nadir 
 
RPE Score 
 
5.9 ± .53 
 
6.4 ± .13** 
  
5.8 ± .74 
 
2.6 ± .56 
 
Rx Range 
 
6 - 8 
 
3 - 4 
  
5 - 7 
 
3 – 4 
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**   Significant differences in RPE scores detected  
              between Nadir training Phases I and  II (p=.003)   
ns   RPE scores reported during standard training were not  
            significantly different between Phases I and  II (p=.24) 
 
 
Figure 6. Changes in RPE Scores during Training Phases I and II 
 
 
 
Changes in Mean Arterial Pressure 
Blood pressure (BP) values were collected during each exercise session in order 
to monitor changes in cardiovascular function. From BP measurements, the mean arterial 
pressure (MAP) was calculated; values of MAP are presented in Table 7. Values of MAP 
were evaluated on the basis of overall change between training phases. Moreover, Nadir 
MAP was assessed for potential treatment-related side effects, specifically hypotension. 
There was no significant difference in MAP for Standard training I versus II (p=0.12). 
Once more, MAP values were not significantly different for Nadir training I versus II 
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(p=0.74). Mean values of MAP for phases I and II of Standard training were combined 
(88.7 and 91.8); this was repeated for Nadir training phases (84.7 and 85.7). To assess 
differences in Standard versus Nadir MAP, combined-phase means were subjected to an 
unpaired t-test analysis. Results are presented in Figure 7. Standard training MAP was 
significantly higher than collected MAP values for Nadir training (p=.005).  
 
Table 7. Effects of Exercise Intervention on Cardiovascular Parameters  
 
Variable 
Phase I 
(n=10) 
Phase II 
(n=11) 
p 
    
Standard MAP (mmHg) 88.7 ± 0.86 91.8 ± 5.71 .12 
Nadir MAP (mmHg) 84.7 ± 2.55 85.7 ± 1.36 .74 
 
Note. Values are presented as means ± standard error; n, number of weeks within each 
phase  
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Figure 7. Changes in MAP during Nadir and Standard Training   
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Changes in Blood Parameters 
 
 Table 8 displays the results of complete blood counts (CBC) and an ELISA 
protein carbonyl assay. Protein carbonyl concentrations were measured only at Nadir 
time points, while the CBC parameters, white blood cells (WBC), red blood cells (RBC), 
hemoglobin (HGB), and platelets (PLT), were collected at Nadir time points (Nadir#) as 
well as immediately prior to each treatment (Chemo#). All parameters were measured 
prior to the first treatment, which served as a baseline from which subsequent data could 
be extrapolated and compared.  Carbonyl concentrations were highest at baseline and 
gradually decreased between baseline and Nadir2. Nadir4 revealed a brief escalation of 
protein oxidation before resuming a downward trend.  Wilcoxon Signed Ranks revealed a 
significant change in carbonyl concentrations across Nadir time points (p=.03). Nadir 
data evidenced compromised WBC concentrations, as depicted by the dramatic reduction 
in cell count; however, cell counts were resilient, as per the return toward baseline values, 
immediately prior to treatment. Platelets gradually decreased until Nadir3, at which point 
the concentrations took on a trend much like that of the WBC, dropping during Nadir and 
increasing prior to treatment. HGB and RBC remained relatively stable. Trends for each 
parameter across time are presented in Figure 8. Each parameter is presented as a 
percentage of the baseline value. 
  
 
 
 
Table 8. Effects of Exercise Intervention on Blood Parameters  
 
Blood Draw Date 
WBC 
(10
3
/µL) 
RBC 
(10
6
/µL) 
HGB 
(g/dL) 
PLT 
(10
3
/µL) 
PRT CRBYL 
(nmol/mg) 
Baseline  Jan 21 6.5 4.05 11.8 242 6.13 
Nadir1 Jan 21 3.7 4.07 11.7 220 5.65 
Chemo2 Feb 12 7 4.25 12.2 207  
Nadir2 Feb 22 3 3.78 11 189 4.55 
Chemo3 Mar 5 5.7 3.97 11.7 189  
Nadir3 Apr 2 4.2 3.86 11.7 244  
Chemo4
* 
Apr 8 - - - -  
Nadir4 Apr 20 3.4 3.82 11.4 153 5.65 
Chemo5 Apr 29 5.8 3.74 11.4 219  
Nadir5 May 11 2.8 3.47 10.6 140 3.8 
Chemo6 May 21 4.6 3.59 11.2 166  
Nadir6 June 3 2.5 3.34 10.6 107 1.47 
 
* The hospital was unable to reproduce CBC results for Chemo4 
7
0
 
  
 
 
 
Figure 8. Change in Blood Parameters  
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CHAPTER V 
DISCUSSION 
Exercise as a remedial strategy continues to gain support, yet proposed benefits 
have primarily been investigated in only a selection of cancer populations, namely, 
cancers of the breast and prostate. This necessitates further exploration in order to extend 
inferences to all cancer types/stages. Markedly sparse is the research in gynecological 
populations. With this in mind, this case study sought to (a) to prescribe an individualized 
exercise intervention for a endometrial cancer survivor receiving high-dose 
chemotherapy, and (b) to determine the feasibility of this exercise program and the 
appropriate progression for its execution. Changes in physical and psychological 
functioning as well as oxidative stress status were described and assessed throughout the 
intervention. 
Cancer patients are frequently subjected to prolonged inactivity, which may 
further promote treatment toxicities. Luckily, current trends encourage exercise, even at 
modest levels, as a means to promote health status in cancer survivors. Even with the 
recent explosion of research, exercise testing norms in cancer populations are limited. For 
this case study, assessment techniques and prescription development were based on the 
research of Schneider et al. (2003) at the Rocky Mountain Cancer Rehabilitation Institute 
(RMCRI). Immediately following her diagnosis, the highly motivated case study subject 
expressed a strong desire to take an active role in the recovery process, which should not
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be considered uncommon, as many cancer survivors are capable of exercise participation 
and desire a way to reclaim self-efficacy (Dimeo et al., 1997). The subject demonstrated 
exemplary adherence over the 21-week study. In total, 63 training sessions were 
documented. Due to the closure of campus offices during weeks 9 and 10, the subject 
performed a modified, but comparable, training regimen during this time unaccompanied 
by the trainer. Excluding the aforementioned account, all training took place at RMCRI 
under the supervision of a trained Cancer Exercise Specialist. 
At the Cancer Survivor Center for Health and Wellbeing in Aspen, Colorado, 
Klika et al. (2008) completed a case study to assess the exercise capacity of a breast 
cancer survivor during and following treatment. Unlike the multidimensional design used 
in our case study, this intervention was solely aerobic in nature. This study neglected to 
assess the effects of exercise on any psychological functioning. In our case study, the 
preservation of QoL and mitigation of fatigue served as primary outcome measures. 
Furthermore, the subject participating in this study had a long history as an elite 
endurance athlete, limiting applicability of findings to highly-trained individuals with 
early stage breast cancer. The intervention was developed from exercise guidelines set 
forth by the United States Olympic Training Center; as a result, training was much more 
aggressive than is generally recommended for even the most ambitious cancer survivor. 
In fact, the case study became symptomatic of overtraining, which could have been 
instigated and/or perpetuated by continued treatment cycles. 
Overtraining typically evolves as a result of poorly planned training along with 
excessive stressors (e.g., load, duration, etc.) and inadequate rest. This process is 
accelerated in patients receiving cancer treatment, as chemotherapy and radiation 
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generate parallel symptomology (e.g., mood disturbance, reduced physical capacity, 
muscle breakdown). With this in mind, our training intervention was designed to 
specifically avoid the development and perpetuation of these symptoms. This study 
demonstrated that a 6-month, combined exercise intervention maintained the physiologic 
and psychologic functioning in a late-stage endometrial cancer survivor receiving high-
dose chemotherapy.  
The single-sample design (e.g., N of 1, single-case research) led to positive and 
negative considerations. Though the depth to which a researcher can delve is limitless, 
statistical significance is rarely obtained from a sample size of one. With this in mind, 
graphical analysis was employed to assess trends in the data; nonparametric statistics 
were utilized only when appropriate. More important to case study research is the 
proposed clinical significance and application. 
I failed to find another study that included pre-treatment baseline data. Assessing 
all variables prior to the first chemotherapy cycle highlights acute side effect 
development. Accordingly, the greatest change in global fatigue (+97%) occurred 
between the baseline and 3-month assessment, suggesting that the immediate effects of 
chemotherapy may be the most distressing. Extreme changes between the baseline and 
final assessments better demonstrate cumulative damage (e.g., chronic effects) of 
antineoplastic agents over time. 
Even with the extreme percent change in fatigue, raw scores were not indicative 
of significant psychological distress (p=.17). Comparison of subject data with Piper 
standard norms indicated that the subject did not experience clinically significant levels 
of global fatigue at any point.  Sensory and affective subscales, however, illustrated 
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marked distress based on the changes from baseline. Unlike behavioral and cognitive 
fatigue, sensory and affective subscales can have severe exercise-related implications. 
Spikes in sensory fatigue, specifically, are indicative of vestibular deficits associated with 
platinum-based analog administration. As a result, balance and coordination become 
compromised. Therefore it becomes imperative to include a greater amount of balance 
work than that prescribed to the subject participating in the case study undertaken by 
Klika et al. (2008). 
QoL data collected over the course of this case study indicated the maintenance of 
psychological wellbeing, as hypothesized.  Our findings are supported by preceding 
research, which also demonstrates a preservation of QoL through programmed exercise 
(Adamsen et al., 2006). 
Physiological parameters measured during baseline, 3-month, and 6-month 
assessments remained stable over the 6 cycles of chemotherapy. Analysis of graphical 
trends illustrated near-linear improvements in both aerobic capacity (VO2peak, mL/ 
kg
-1
/min
-1
) and muscular strength (1-RM weight, lbs). However, Wilcoxon Signed Ranks 
analysis did not deem changes in physiologic variables to be significant. 
 Successive improvements did not translate directly to increased training load. In 
fact, modifications were more dependent on RPE scores and subjective feedback of the 
case study; a 10% reduction in the strength training load was imposed following both the 
3-month and 6-month assessment. Aerobic training loads remained relatively unchanged 
over the course of the study. Through the tedious scrutiny of RPE scores and subjective 
complaints, training loads were adjusted to meet the needs of our subject, as the aim of 
this investigation was to create an exercise plan that could be maintained over time. 
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Because platinum-based drugs are known to affect cardiovascular function, mean 
arterial pressure (MAP) was used to evaluate changes in the systemic arterial pressure. 
Variations could indirectly indicate treatment-related alteration to systemic vascular 
resistance or cardiac output.  Arterial pressure did not differ significantly between study 
Phases I and II for standard (p=.12) or Nadir (p=.74) training. Though standard training 
Phases I and II did not diverge significantly, arterial pressures were approximately 7 
mmHg higher during Phase II. This response can be accounted for by the discontinued 
use of prescription medication, Lisinopril, following an early complication; the 
hypotensive response became compounded by the interaction of Lisinopril with 
carboplatin. 
Training Phases I and II were combined and assessed over the 21-week study 
(Nadir I and II versus standard I and II). Nadir pulse pressure was significantly lower 
than standard training MAP (p=.005). This hypotensive response shortly after drug 
administration is characteristic of many platinum-based chemotherapy agents and 
highlights the importance of reduced training loads during Nadir. 
Circumference measurements served as a tool for the evaluation of lymphedema 
development/progression. Lower limb circumference remained stable, as indicated by 
assessment data.  Lymphedema in the lower extremities was a primary concern. In early 
March, deteriorating renal function required that a kidney stent be put in place to ensure 
unobstructed circulation to the lower extremities. Additionally, lymph node swelling 
blocked lymph flow into and out of the right leg which caused initial leg lymphedema.  
The swelling in the right leg was the symptom that alerted the medical team to find the 
endometrial cancer. With vasculature compromised in this region, the pressure needed to 
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ensure adequate circulation placed a great deal of stress on the heart. Lisinopril ingestion 
ameliorated this stress, and interestingly, the side effects of treatment induced similar 
actions, decreasing the blood pressure.  
Treatment-related toxicities, cachexia, fatigue, and compromised QoL, are 
thought to be exacerbated through states of augmented oxidative stress. Reduced levels of 
oxidative stress may serve to alleviate toxicities brought on by treatment. Biochemical 
analysis of protein carbonyls indicated a significant reduction (p=.03) in protein oxidation 
from baseline assessment. Blood draws 1-3 illustrate a downward trend in carbonyl 
concentration (6.13, 5.65, and 4.55 nmol/mg). Each of the first 3 treatments were 
administered every third week as scheduled, and Nadir draws were collected 10 days 
after treatment.  
Between the third and fourth treatment cycle, an additional 14 days elapsed due to 
vacation time and medical procedures unrelated to the cancer. It is likely that this 
extended span of time fostered tumor progression and may very well explain the restored 
increase in carbonyl concentrations between Nadir 3 and 4. Protein carbonyls measured 
between Nadir 4-6 recommenced a descending trend (5.65, 3.40, and 1.67 nmol/mg). 
Reduced protein degradation (likely associated with alleviated cancer cachexia) may 
explain sustained muscular strength. 
Results from complete blood panels collected for each treatment and Nadir time 
point further elucidate changes within hematological parameters. As is typically the case, 
WBC concentrations revealed drastic reductions during Nadir (approx. 10 days post-
chemo), before returning to heightened values immediately prior to treatment. While 
erratic, the up-and-down trend highlights a capacity to overcome treatment-facilitated 
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damage, likely heightened by exercise training. With compromised immune function 
common to those patients undergoing treatment, the time-dependent restitution of WBCs 
was fundamental in avoiding flu/cold viruses. Hemoglobin concentrations fluctuated very 
little over the course of the study. An essential transport protein, hemoglobin likely 
evaded significant destruction (e.g., oxidation) through exercise; this postulation is 
directly in line with the carbonyl assay results. While overall, blood counts regress over 
time, at no point did hematological values stall the administration of treatment. The 
ability to maintain the prescribed dosing schedule is directly related to the subject‟s 
continued optimistic prognosis.  
Shortly after completing the sixth cycle of PC, the subject underwent medical 
imaging to evaluate the trajectory of the tumor. Results indicated that tumor growth had 
been halted; however, nodal involvement in the region meant that surgical removal would 
not serve as an effective means to ensure a cancer-free prognosis. The cancer was 
deemed controllable, but not likely curable.  
As a result, PC will be administered continuously, approximately every fourth 
week in hope of controlling tumor growth. Chemotherapy used for non-curative intent is 
just as valuable, if not more so, in incurable cancers as it can impact survival by 
prolonging life. Oncologists hope to increase the span of time between cycles to limit the 
noxious drug effects. With this news, the capacity to attenuate psychological distress and 
maintain physical capacity has become more crucial than ever. The cumulative nature of 
chemotherapy drugs educes destruction systems throughout the body. This study has 
demonstrated that exercise training can attenuate the effects of treatment, and even lead 
to physiological and psychological improvements.  
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The significance of training load modification served as, perhaps, the most 
influential concept drawn from this case study. For patients receiving or expected to 
receive long bouts of treatment, the goal of exercise programming is a preservation of 
physical and psychological functioning. To offset the side effects of therapy and attenuate 
certain, unavoidable declines, training loads will likely be reduced. In this case study, the 
subject‟s ability to preserve muscular strength and cardiorespiratory fitness is likely due 
to modifications made to training intensity. The subject‟s unwavering resilience 
highlights sustained QoL and wellbeing. Taken together, exercise training appears to be a 
safe and effective means to improve the cancer survivorship outlook. 
Conclusion 
The growing cancer survivor population presents a welcomed challenge to health 
care providers and efforts that integrate nutrition and exercise as a means to enhance QoL 
continue to gain support. Exercise, both during and following treatment, is encouraged in 
order to attenuate the adverse effects brought on by antineoplastic drugs.  
This case study demonstrated that multimodal exercise training of adaptable 
intensities is an effective strategy for maintaining physical and psychological function in 
a cancer survivor receiving palliative chemotherapy to control tumor growth. The 
preservation of physical capacity with concurrent reductions in psychological distress has 
been demonstrated in many other studies (Schneider et al., 2007; van Weert et al., 2005).  
Collectively, upper and lower body strength improved over the course of the 6-
month intervention. Aerobic capacity, as per VO2peak, illustrated improvement as well. 
QoL remained stable and global fatigue scores were not indicative of psychological 
distress. Observed improvements may be attributable to modifications made to training 
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loads at various points during the study. Permitting necessary adjustments of training 
loads maintained the central objective of this case study, which was to construct a 
training program that could be continued over time. The significant reduction in protein 
carbonyls (e.g., protein oxidation) suggests a preservation of muscle integrity. Moreover, 
complete hematology panels (e.g., WBC, RBC, HGB, and PLT) revealed a collective 
resistance against treatment-related damage in the recurring escalation toward initial 
values. Owing to exercise training, a higher percentage of each baseline value was 
achieved than would have otherwise been observed had the subject remained sedentary 
over the course of the study.  
The exercise design applied in this case study appears to have merit, which may 
assist health professionals seeking direction in the implantation of an exercise program 
for an endometrial cancer survivor. The outcomes of this case study emphasize that 
moderate to high intensity exercise are not beyond the realm of possibility for late-stage 
cancer survivors. Results from the baseline assessment should be assessed to establish 
initial exercise intensities. Preliminary intensities of 60-70% 1-RM and 60-70% HRR are 
appropriate for muscular strength and aerobic exercise, respectively. Establishing the 
intensity as a range of values allows for modification throughout the intervention. During 
Nadir, training loads should be reduced to avoid exacerbating noxious side effects during 
a period of low energy and compromised immunity. Nadir intensities of 40-50% 1-
RM/HRR were well tolerated; even low- to moderate intensities illustrated sustained 
physiological capacity during a time in which our patient would have otherwise been 
inactive. 
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Exercise sessions should be approximately an hour in length in order to include 
all intervention components (e.g., strength, aerobic, balance). A training frequency of 3 
days/week is recommended to allow for adequate recovery between workouts, while still 
providing ample stimuli to elicit physiological training effects. Patients should be 
monitored continuously as per RPE scores and subjective feedback. Fluctuations in 
subjective parameters may indicate the need for training load adjustment.  The delineated 
exercise guidelines are recommended for achieving outstanding adherence and sustained 
physical and psychological capacities in endometrial cancer survivors.  
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APPENDIX A 
RPE SCORES FOR A 21-WEEK EXERCISE INTERVENTION
  
 
 
RPE Scores for a 21-Week Exercise Intervention  
 
 
Values are means of RPE scores for each exercise in a given week; 
† indicates first week after chemo (Nadir), reduced training loads for weeks 1, 4, 7, 12, 15, and 18 
Week # 1† 2 3 4† 5 6 7† 8 9 10 11 12† 13 14 15† 16 17 18† 19 20 21 
                      
Chest Press 8.3 8.7 8.3 7.5 8.3 9 4.5 2.8 2.8 9 8.5 3.3 8.2 8 3.2 8.8 8.7 4.3 7.2 6.7 6 
Military Press 9.2 7.8 8.3 9.3 6.7 7.8 8.2 9 9.4 10 10 4.2 7.7 6.8 3.3 6.8 7.3 7.2 7.7 7.5 7 
Lat Pull 6 7.2 7.3 5 6.7 6.8 2.2 4 5 7 6.5 1.3 7 6.5 1.8 7 6.7 3.3 6.5 6.8 6.2 
Leg Press 6.6 6.3 7.7 5.7 7.7 7 3.2 6 6.5 7.8 7 2.2 8.6 8.2 2.8 7 7.1 5.0 7.1 6.6 6.1 
Leg Extension 5.2 5.5 6.5 6 6.5 6.2 3.2 3 3 6 7 2.5 6.3 6.3 2.3 5.7 6.5 2.9 6.3 6.5 7.1 
Leg Curl 4.5 5.2 5.8 5 6.5 6 4.5 2.7 2.7 6 6 1.5 6.3 6 1.7 6 6 3.2 6.2 7.1 6.5 
Tricep Extension 4.2 4.3 3 4 4.5 5 2.8 3 3.2 3.3 4 1.8 5.3 3 1.8 2 2.3 3.0 3.5 4.2 4.0 
9
8
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